Structural and functional investigation of the innate immune receptor MDA5 and its inhibition by paramyxoviral V proteins by Motz, Carina
   
Dissertation zur Erlangung des Doktorgrades                                                                 
der Fakultät für Chemie und Pharmazie                                                                        
der Ludwig-Maximilians-Universität München 
 
 
 
 
Structural and functional investigation                                               
of the innate immune receptor MDA5 and its inhibition                         
by paramyxoviral V proteins 
 
 
 
 
 
Carina Beate Motz 
aus 
Fulda, Deutschland 
 
 
2013 
 
 
 
   
Erklärung  
Diese Dissertation wurde im Sinne von § 7 der Promotionsordnung vom 28. November 2011 von 
Herrn Prof. Dr. Karl-Peter Hopfner betreut.  
 
 
 
Eidesstattliche Versicherung  
Diese Dissertation wurde eigenständig und ohne unerlaubte Hilfe erarbeitet.  
 
 
 
München, am 14.5.2013 
 
 
 
 
 
 
___________________________________ 
                                                                                                           Carina Beate Motz  
                                                                                        
 
 
 
 
 
 
 
 
 
 
 
 
Dissertation eingereicht am          14.5.2013 
1. Gutachterin / 1. Gutachter:      Prof. Dr. Karl-Peter Hopfner 
2. Gutachterin / 2. Gutachter:      Prof. Dr. Karl-Klaus Conzelmann 
Mündliche Prüfung am                8.7.2013 
   
This thesis has been prepared from April 2010 to February 2013 in the laboratory of Prof. Dr. Karl-Peter 
Hopfner at the Gene Center of the Ludwig-Maximilians-University of Munich (LMU).  
 
 
 
Parts of this thesis have been published: 
 
Motz C., Schuhmann K.M., Kirchhofer A., Moldt M., Witte G., Conzelmann K.K., Hopfner K.P. 
“Paramyxovirus V proteins Disrupt the Fold of the RNA Sensor MDA5 to Inhibit Antiviral Signaling.” 
Science (8 February 2013: Vol. 339, no. 6120, pp. 690-693). 
 
 
 
Parts of this thesis have been presented at an international conference: 
 
Talk at the 23rd Annual Meeting of the Society for Virology, 6th–9th March 2013, Kiel, Germany. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
„Ein hartnäckiger Begleiter der Erkenntnis ist die  
Unwissenheit über die eigene Unwissenheit.“ 
 
Stanislaw Lem, Also sprach Golem 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 TABLE OF CONTENTS  
  i 
Table of Contents 
 
1 Introduction………………………………………………………………...1-23 
1.1  Pattern recognition receptors are key sentinels of the innate immune system…………...……1-5 
1.1.1 Universality versus specificity……………………………………………………………………......1 
1.1.2 Toll-like receptors (TLRs)……………………………………………………………………………2 
1.1.3 NOD-like receptors (NLRs)………………………………………………………………………..2-3 
1.1.4 The AIM2 inflammasome…………………………………………………………………………….3 
1.1.5 Other DNA sensors……………………………………………………………………………...........3 
1.1.6 RIG-I like receptors (RLRs)………………………………………………………………………..3-4 
1.1.7 Components of the innate immune system do not act in isolation……………………………...….4-5 
1.2 The RIG-I like receptor family senses viruses by recognizing RNA patterns…………..……..5-10  
1.2.1 RLRs share a similar domain organization but function divergently in antiviral immunity……….5-8 
1.2.2 The RD determines the specificity of RLRs for different RNA ligands……………………….....8-10 
1.3 The structural basis for antiviral signal activation by RLRs……….…………………...…….10-15 
1.3.1 RIG-I is activated by a conformational switch that triggers signaling………………………......10-12 
1.3.2 The activation of MDA5 shows mechanistic similarities and differences to RIG-I………..……12-14 
1.3.3 The function of ATP hydrolysis in the activation of RLRs is unknown……………………...…14-15 
1.4 RIG-I and MDA5 use the adaptor MAVS to induce cytokine production……………………15-19 
1.4.1 Ubiquitin and the polymerization of MAVS propagate the antiviral signaling cascade……...…15-16 
1.4.2 The activated transcription factors NF-κB, IRF3 and IRF7 drive the cytokine production……..16-17 
1.4.3 CARDless LGP2 regulates the antiviral activity of RIG-I and MDA5……………..………...…17-19 
1.5 The paramyxoviral V protein is a potent cytokine antagonist…………………...……………19-23 
1.5.1 The V protein is a non-structural protein required for viral pathogenesis……………………….19-20 
1.5.2 The V protein sabotages the innate immune response at several levels…………………………20-21 
1.5.3 The V protein specifically binds and inhibits MDA5…………………………………………....22-23 
1.6 Objectives……………………………………………………...……………………………………...23 
 
 
 
 
 
 TABLE OF CONTENTS  
  ii 
2 Material and Methods …………………………………………….……...24-42 
2.1 Materials……………………………………………………………………………………………...24 
2.2 Methods…………………………………………………………………………………………...24-42 
2.2.1 General molecular biology methods…………………………………………..…………...…….24-25 
2.2.1.1 Cloning……………………………………………………………………………………………………….………….….24 
2.2.1.2 Site-directed mutagenesis……………………………………………………………………....……………….………….24 
2.2.1.3 Heat shock transformation of Escherichia coli XL1-Blue (K12)………………………………….…………………….…25 
2.2.1.4 Isolation of plasmid DNA from Escherichia coli XL1-Blue (K12)……………………………………………………..…25 
2.2.1.5 Determination of nucleic acid and protein concentrations………...…………………………………………………….…25 
2.2.2 General bioinformatics methods…………………………………………………………...………..25 
2.2.2.1 Protein sequence alignments and secondary structure predictions……………………………………………...……….…25 
2.2.2.2 Structure visualization and analysis……………………...……………………………...………………………………….25 
2.2.3 Small scale protein testexpression ……………………………………………………………….…26 
2.2.4 Large scale protein expression………………………………………………………………………27 
2.2.5 Large scale purification of MDA5 and PIV5 V proteins and their complexes……………….…28-29 
2.2.6 ATPase assays…………………………………………………………………………..…………...29 
2.2.7 Static light scattering (SLS) measurements…………………………………..…………...……..30-31 
2.2.8 Small-angle X-ray scattering (SAXS) of protein solutions …………………………………...…....31 
2.2.9 Reductive methylation …………………………………………………………….…………….….32 
2.2.10 Large scale purification of Fab fragments and triple complex formation ………………..………..32 
2.2.11 Crystallization of the ssMDA5:PIV5 V protein core complex…………………………...…….32-33 
2.2.12 Structure determination……………………………………………………………………..….33-41 
2.2.12.1 Principles of X-ray structure analysis………………………………………………………………………………….33-34 
2.2.12.2 Principles of SAD pahsing…………………………………………………………..…………………………...……35-40 
2.2.12.3 Structure determination of the ssMDA5:PIV5 V protein core complex………………………………………..……..40-41 
2.2.13 Analytical size exclusion chromatography……………………………….………………………..41 
2.2.14 Differential scanning fluorimetry experiments …………………………………………..………..41 
2.2.15 Electrophoretic mobility shift assays (EMSAs)…………………………………….……...…..41-42 
2.2.16 Electron microscopy …………………………………………...…...……………………………..42 
 
 
 
 
 
 
 TABLE OF CONTENTS  
  iii 
3 Results………………. …………………………………………….……...43-65 
3.1 Recombinantly expressed full length MDA5 is a functional protein………………………….43-45 
3.2 Optimization of protein constructs for crystallization……………………………………...….46-49 
3.3 Crystallization of the ssMDA5:PIV5 V protein core complex………………………………....49-52 
3.4 The paramyxoviral V protein disrupts the fold of the MDA5 SF2 ATPase domain…………52-56 
3.5 Differences in residue conservation enable RIG-I to evade V protein recognition……….….57-59 
3.6 The PIV5 V protein has to unfold itself to disrupt the fold of MDA5…………………….…..59-62 
3.7 V protein binding has dual impact on the function of MDA5…………………………………63-65 
 
4 Discussion………………………………………………………….….…...66-80 
4.1 A structure-derived model for MDA5 inhibition by paramyxoviral V proteins…………..…66-72 
4.1.1 Which energy source drives the unfolding processes that accompany V protein binding?..........69-70 
4.1.2 Known β-strand displacement mechanisms in other biological processes…...………………….70-72 
4.2 Is the RD of RLRs able to switch between two binding modes?................................................72-73 
4.3 V protein binding to other RLR family members and its functional impact…………………73-78 
4.3.1 Engineering of RIG-I inhibition by paramyxoviral V proteins…………………………...……..75-77 
4.3.2 Indirect inhibition by paramyxoviral V proteins via LGP2…………………………………………78 
4.3.3 Viral pressure on the evolution of RLRs……………………………………………………………78 
4.4 The paramyxoviral V protein as a universal immune targeting tool…………………….……79-80 
 
5 Summary..………………………………………………………….……...81-82 
6 References………………………………………………………...……….83-94 
7 List of abbreviations……………………………………………….……..95-97 
8 Acknowledgments………………………………………………….……..…..98 
9 Curriculum vitae…………………………………………………….…….…99 
 
 
 
 I INTRODUCTION  
  1 
1. Introduction 
 
1.1 Pattern recognition receptors are key sentinels of the innate immune system  
Any organism that passes the physical and chemical barriers of the body encounters a further level of 
defense, the innate immune system of the host. Its crucial role in the early recognition of invading 
pathogens as bacteria, viruses, protozoa and fungi is emphasized by the fact that defects affecting the 
components of the innate immune response are almost always lethal (1). The selective pressure imposed 
on multicellular organisms by infectious microorganisms directed the evolution of a large class of 
germline-encoded receptors, known as pattern recognition receptors (PRRs). This class of innate immune 
receptors, which comprises membrane-bound as well as soluble receptor proteins, was named after their 
capability to sense particular molecular signatures on pathogens called pathogen-associated molecular 
patterns (PAMPs). In this capacity, PRRs represent an essential key component of the host innate immune 
defense (2, 3).  
 
1.1.1 Universality versus specificity 
The term “pattern”, which Janeway introduced already in 1989, reflects the basic molecular concept of 
PAMP recognition by host PRRs. PAMPs are characterized by a certain degree of structural invariance 
since they represent molecular structures that are essential for the survival of the pathogen. The resulting 
evolutionary conservation of these structures comprises that they are shared by large groups of pathogens. 
For example, lipopolysaccharides (LPS) can be found in the outer membrane of all gram-negative 
bacteria and share the conserved lipid A. Serving as common molecular pattern for the PRR TLR 4, lipid 
A enables the host to detect the presence of any gram-negative bacterium. In this way, a relatively small 
number of germline-encoded receptors can recognize a broad range of molecular structures associated 
with pathogens (3).  
However, the interaction between conserved PAMPs and PRR is not only characterized by 
universality, but also by specificity. To eliminate the invading pathogen and to induce an antipathogenic 
state of the host, the innate immune system employs various defense mechanisms that involve e.g. the 
production of proinflammatory cytokines, activation of the complement system, induction of apoptosis, 
phagocytosis or autophagy (2). To avoid self-damage of the host cells and tissues, the patterns 
evolutionary selected for the recognition by PRRs must have been absolutely distinct from the self-
antigens. This selected component of specificity allows PRRs to distinguish infectious nonself from 
noninfectious self and thereby contributes to the required and tight regulation of the immune response (3). 
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1.1.2 Toll-like receptors (TLRs) 
The discovery of PRRs is linked to the identification of the Toll protein in Drosophila species in 1985. 
The identification of mammalian Toll-like receptors (TLRs) succeeded in the mid 1990s based on 
homology to the Drosophila protein. The finding that they mediate the recognition of pathogens by the 
innate immune system exposed the existence of PRRs. The TLRs are to date the most extensively studied 
PRRs. A total of10 TLR family members have been identified in humans and 12 in mice. They all belong 
to the type I transmembrane glycoproteins and bind PAMPs via leucine rich repeats (LRRs) in their 
extracellular portion. A cytoplasmic Toll/interleukin-1 receptor (TIR) domain provides downstream 
signaling. Based on the nature of the recognized PAMPs, the TLRs can be divided into subfamilies: 
TLR1, 2, 4 and 6, which are primarily expressed on the cell surface recognize lipids derived from bacteria 
and viruses. In contrast, TLR3, 7, 8 and 9 are exclusively located within endocytic compartments and 
bind to bacterial and viral nucleic acids (2, 4, 5).   
 
1.1.3 NOD-like receptors (NLRs) 
The recognition by membrane-bound TLRs is restricted to extracellular pathogens. Since the viral 
replication cycle for instance proceeds inside the cell, TLR recognition is supported by various 
cytoplasmic receptors that contribute in an essential way to an effective immune response (6). The family 
of NOD-like receptors (at least 23 members in humans) mediates sensing of a broad ligand spectrum from 
all classes of pathogens within the cytoplasm of cells. These receptors consist of three domains: The N-
terminus carries a signaling domain as for example a pyrin domain (PYD) or a caspase recruitment 
domain (CARD). These domains are known to function as protein interaction modules and therefore 
thought to direct homo- or heterotypic binding. The signaling domain is followed by a nucleotide-binding 
and oligomerization domain (NOD) that is believed to trigger an ATP-dependent self-oligomerization of 
the receptor molecule upon ligand binding. The C-terminus accommodates a series of  LRRs which are, 
as in the case of TLRs, implicated in the binding of the PAMP (4, 7).   
 NOD1 and NOD2 were the first described NLRs that are involved in cytoplasmic microbial 
sensing. Both molecules are activated by peptidoglycan components of the bacterial cell wall and trigger 
NF-κB-dependent production of inflammatory cytokines (7). Other stimuli are able to drive the assembly 
of certain NLRs (e.g. NALP, NALP3, NLRC4, NAIP5) into large, multiprotein signaling complexes, 
named “inflammasomes”(4). The formation of an inflammasome complex involves the scaffold protein 
ASC (apoptosis-associated speck-like protein containing a CARD). Its N-terminal PYD and its C-
terminal CARD enables ASC to function as a bipartite adaptor molecule that recruits members of the 
NLR family as well as non-NLR proteins (7). Among ASC recruited non-NLR proteins are various 
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procaspases that undergo proteolytic cleavage and thus activation upon inflammasome association. The 
in- complex activated caspases in turn cleave substrates to produce mature inflammatory cytokines (the 
substrates include for example pro-IL-1  and pro-IL-18) or to initiate apoptosis (4).  
 To date it is still unresolved whether NLRs activation is induced by direct binding of the PAMP 
ligand or rather by indirect sensing of particular stress-activated signaling pathways that go along with 
invasion of cells by pathogens. In this context, it has been proposed that the stress events potassium efflux 
and generation of reactive oxygen species (ROS) affect the NLR response, but the precise activation 
mechanism of NLRs still remains unclear (5, 6).  
 
1.1.4 The AIM2 inflammasome  
Although AIM2 shares the characteristic N-terminal pyrin signaling domain with some NLRs, AIM2 
(absent in melanoma 2) does not represent a typical NLR. Unlike NLRs, AIM2 harbors a C-terminal HIN-
200 domain that enables the receptor molecule to bind directly to viral dsDNA within the cytoplasm. The 
PYD allows activated AIM2 the formation of an inflammasome via a homotypic interaction with the 
adaptor protein ASC. The AIM2 inflammasome is associated with procaspase-1 whose activated form 
caspase-1 converts pro-IL-1β and pro-IL-18 into mature cytokines (4-6, 8).  
 
1.1.5 Other DNA sensors 
It is known that cytoplasmic DNA can induce the production of proinflammatory cytokines independent 
from TLRs or AIM2, pointing towards the existence of additional DNA sensors within the cell. The 
protein STING (stimulator of interferon genes) localized at the ER-membrane is appointed to be a critical 
component in the signaling pathway of dsDNA recognition. Since STING does not show a direct binding 
of dsRNA, it is more likely that it functions downstream as a signaling adaptor protein of an yet 
unidentified DNA sensor (4, 5, 9). The PYHIN (pyrin and HIN domain-containing protein) protein family 
member IFI16 (interferon-inducible protein 16) might be a promising bridging factor between dsRNA 
recognition and STING signaling. It contains two DNA-binding HIN domains and has been shown to be 
recruited to synthetic dsDNA and STING in the cytoplasmic compartment (8).  
 
1.1.6 RIG-I like receptors (RLRs) 
The family of RIG-I like receptors comprises the three members RIG-I (retinoic acid inducible gene I), 
MDA5 (melanoma differentiation associated protein 5) and LGP2 (laboratory of genetics and physiology 
2). This family plays a crucial role in the detection of viral RNAs in the cytoplasm of infected cells. Their 
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function as viral RNA sensors, which is explained in detail in sections 1.2, 1.3 and 1.4 of the introduction, 
is supposed to be assisted by the OAS/RNAseL pathway. In the presence of intracellular viral dsRNA, 
OAS (2’-5’ oligoadenylate synthase) is activated and produces a specific nucleotide second messenger, 
namely 2’-5’ oligoadenylate. In response to this second messenger, RNAseL cleaves and processes viral 
nonself as well as cellular self RNAs. The RNAseL products are believed to serve as potent RNA ligands 
for members of the RLR family (1, 10, 11).  
Beside their function as RNA receptors, RLRs are also able to act as indirect DNA sensors by 
recognizing viral transcripts produced by the RNA polymerase III (Pol III). Pol III normally transcribes 
cellular DNA to synthesize ribosomal 5S rRNA, pre-tRNA and other small RNAs. In infected cells, 
viruses employ the host Pol III to generate small, noncoding RNAs that can antagonize the host immune 
response, but can be also recognized by RLRs. By transcribing a particular region of the DNA virus 
genome, Pol III synthesizes 5’-triphosphate ends, which are known to effectively activate RIG-I (see 
section 1.2). Thus, the Pol III-RIG-I pathway nicely illustrates the evolutionary arms race between the 
host and the virus (8).          
 
1.1.7 Components of the innate immune system do not act in isolation  
Studies suggest that the introduced PRR families are not sufficient to explain the protective immune 
response that can be observed against a wide range of various infectious agents. Indeed, the numbers of 
PRRs, but also their ligands continue to increase, indicating that many important PRRs are still 
undiscovered (4, 7).  
 But so far signaling pathways triggered by PRRs seem to share a general concept: Signaling 
domains within the receptor molecule allow the interaction with certain signaling adaptor proteins (e.g. 
Myd88, Trif, TRAM, Mal, MAVS, RIP2), which operate in cascades and activate terminal effector 
proteins such as caspases (e.g. caspase-1 or caspase-5) and transcription factors (e.g. NF-κB, IRF3 and 
IRF7). The effector proteins induce finally the production of type I interferons and other various 
proinflammatory cytokines or chemokines as well as anti-viral proteins. All these signaling pathways do 
not act in isolation, but have been shown to be synergistic and cooperative. This interplay between the 
different PRR families seems to permit the effective orchestration of the innate immune response (7).  
 Not only the components of the innate immunity are interlinked, but there is also intensive 
communication between the pathways of the innate and adaptive immune system. Besides its role in the 
early recognition of pathogens, the innate immune system contributes fundamentally to the proper 
activation, maturation, priming and shaping of the adaptive immune response. In this capacity, the innate 
immune system is not longer regarded as a primitive evolutionary rudiment that functions in separation of
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the adaptive immune system. Instead, the innate immunity and the adaptive immunity are perceived as 
two tightly connected systems that act in concert to provide efficient and broad protection of the host 
organism (1, 2).  
 
 
 
1.2 The RIG-I like receptor family senses viruses by recognizing RNA patterns  
In addition to TLRs, the RIG-I like receptor (RLR) family represents the second class of PRRs that senses 
RNA PAMPs and plays a major role in inducing an antiviral response. But unlike the membrane-bound 
TLRs, the three RLR family members RIG-I, MDA5 and LGP2 are localized and distributed in the 
cytoplasm where they bind to specific RNA patterns that occur in the host cell during a virus infection 
(see also sections 1.1.6  and 1.2.1). RIG-I, the founding member and eponym of the family, as well as 
MDA5 were initially characterized as RNA helicases that showed ATPase activity upon binding to 
dsRNA and were therefore assumed to be involved in the induction or mediation of an innate antiviral 
response (12, 13). Various studies have since revealed RIG-I and MDA5 as major factors in virus 
recognition and activation of antiviral signaling pathways (14, 15). LGP2, which was originally identified 
as a gene of the Stat3/5 locus highly expressed in mammary tissues (16), complements the RLR family 
and is believed to play an important role in the modulation of the signaling by its homologs RIG-I and 
MDA5 (17-23) (see also section 1.4.3).  
 
1.2.1 RLRs share a similar domain organization but function divergently in antiviral immunity 
RIG-I, MDA5 and LGP2 belong to the superfamiliy 2 (SF2) helicases or ATPases. They share a central 
DECH box RNA helicase domain (named after the conserved amino-acid sequence of the Walker B 
motif)  that exhibits ATP hydrolysis as well as RNA binding capacity (14, 24, 25). The DECH box RNA 
helicase domain contains the two characteristic RecA-like domains (also known as Rossmann fold), that 
define the SF1 and SF2 helicases (see figure 1). These two domains form an active site for ATP binding 
and hydrolysis at their interface by clustering conserved motifs in a central core region. DECH box 
helicases possess eight conserved motifs (namely motifs I (Walker A motif), Ia, Ib, II (Walker B motif), 
III, IV, V and VI) that were shown to be involved in the regulation of the ATPase activity and some of the 
motifs also mediate RNA binding (24, 26).  
 RIG-I like helicases gain uniqueness and functional specificity through their accessory domains 
that complement the helicase core (see figure 1). For instance, the two RecA-like domains are separated 
by an unusual α-helical insertion domain that resembles the archaeal Hef DNA helicase (27). In
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addition, the second RecA-like domain is followed by a C-terminal extension that contains a zinc-binding 
domain with structural homology to GDP/GTP exchange factors of Rab-like GTPases (28). This so called 
regulatory domain (RD) as well as the alpha-helical insertion domain have been shown to participate in 
the binding of RNA ligands in an essential way (26, 29-31) (see also sections 1.2.2 and 1.3). However, 
sole RNA binding by RLRs is not sufficient to induce an antiviral activity, but relies on the presence of a 
CARD interaction motif. RIG-I and MDA5 (but not LGP2) are equipped with two tandem CARDs, which 
are localized at the N-terminus and which serve as signaling domains that mediate binding to the adaptor 
protein MAVS (see also section 1.3 and 1.4). Their crucial role in triggering antiviral response is 
emphasized by the fact that overexpression of the isolated RIG-I CARDs is sufficient to confer IFN 
production, showing that the CARDs are indeed responsible for antiviral signaling (12). 
 
 
CARD1 CARD2 RDN-RecA C-RecAInsertion
CARD1 CARD2 N-RecA C-RecAInsertion
RDN-RecA C-RecAInsertion
RD
RIG-I   106 kDa
5‘ppp-ss/dsRNA          
blunt end dsRNA   
MDA5   116 kDa
long dsRNA
poly I:C
LGP2   75 kDa
blunt end dsRNA
SF2 ATPase domain
SF2 ATPase domain
SF2 ATPase domain
 
 
Figure 1: Domain organization of the three RIG-I like receptor family members RIG-I, MDA5 and LGP2 with 
indicated molecular weight and specified RNA ligands. CARD = caspase recruitment domain; SF2 = helicase 
superfamily 2, RD = regulatory domain or RNA binding domain. Adapted from (14, 25).  
 
 
 Despite the similarities that they share in sequence and domain organization, RLRs show 
divergent function concerning the groups of viruses that they recognize. RIG-I mainly detects negative- 
stranded viruses (such as influenza virus (Orthomyxoviridae), Sendai virus (Paramyxoviridae), Newcastle 
disease virus (Paramyxoviridae) and vesicular stomatitis virus (Rhabdoviridae)), but also some positive- 
stranded viruses (such as hepatitis C virus (Flaviviridae) and Japanese encephalitis virus (Flaviviridae)). 
In contrast, MDA5 responses primarily to double-stranded and positive-stranded viruses, especially to 
members of the Picornaviridae family (such as encephalomyocarditis virus (EMCV), Theiler’s murine
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encephalomyelitis virus (TMEV), coxsackievirus B3 (CVB3)) and to murine norovirus (Caliciviridae) 
(14, 32-38).    
 This divergence in virus recognition by RIG-I and MDA5 is reflected in the actual structural 
RNA patterns, which RLRs detect on the molecular level and which allow them to distinguish different 
RNA viruses. In 2006, two independent studies identified 5’-triphosphate (5’-ppp) containing RNAs as 
RIG-I ligands (39, 40). Indeed, many RNA virus that are recognized by RIG-I carry genomes that contain 
5’-ppp ends or synthesize RNAs with 5’-ppp ends during their replication cycle in the host cell. The 
particles of negative-stranded viruses import a RNA-dependent RNA polymerase (RdRp) that allows 
those viruses the immediate transcription of their genome after entering the cell. Most RdRps do not rely 
on a primer to initiate synthesis, resulting in transcripts that exhibit a triphosphate group at their 5’-end 
(41, 42). But activation of RIG-I does not necessarily require viral replication within the cell. It has been 
shown that RIG-I is able to induce IFN response already before viral RNA synthesis has started by 
detecting incoming, encapsidated RNA virus genomes, which carry a 5’-ppp dsRNA “panhandle” 
structure (43, 44).  
The 5’-ppp moieties are specific for viral RNA genomes or transcripts as most of the 5’-ppp 
groups that emerge from host transcription are either removed by adding a cap structure (in case of 
mRNA) or by processing (in case of tRNA and rRNA). To that effect, 5’-ppp moieties allow RIG-I to 
distinguish between self and non-self (34). Albeit RIG-I shows highest affinity for 5’-ppp dsRNA, it is 
known that RIG-I can also recognize and bind blunt-ended dsRNA (as LGP2 does, see also sections 1.2.2 
and 1.4.3) (31, 45-47). This indicates that other, not yet identified and maybe multiple features of RNA, 
which differ between viral and cellular RNAs, might be involved in the discrimination of self and non-
self by RLRs (48).   
 Little is known about the nature of the RNA patterns that activate MDA5. Its physiological 
ligands are scarcely characterized and as yet poorly defined. Uncapped 5’-ppp RNA is absent in viruses 
known to be detected by MDA5. Rather, it has been suggested, that ribose 2’-O-methylation provides a 
molecular signature for MDA5 to differentiate between self and non-self mRNA (49). However, it is 
generally assumed that MDA5 is activated by long, double-stranded RNA molecules, which are regarded 
as “intrinsically” non-self (47). It is known for a long time, that MDA5 can be activated by transfection of 
poly(I:C), a synthetic dsRNA analog exceeding 2 kbp in length. RNase III digestion of poly(I:C) to    
~300 bp fragments converts poly(I:C) from a MDA5 activator to a RIG-I activator, showing that RIG-I 
does not necessarily rely on the presence of 5’-ppp groups and prefers shorter RNA ligands as MDA5 (35, 
47). This original finding, that MDA5 recognizes long dsRNA, is supported by several further studies. 
Additional transfection-based experiments showed that MDA5 responds to the L segments of the
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MDA5 + poly I:CMDA5 + 2012 bp dsRNA
 
 
Figure 2: Filament formation of MDA5 on long dsRNAs visualized by negative-stain electron microscopy (53, 54). 
 
 
reovirus genome (4 kbp in length) with induction of type I interferon production (50). Furthermore, the 
very large RNA species generated during EMCV or vaccinia virus infection were identified as specific 
MDA5 activators, indicating that MDA5 requires higher-order RNA structures to function (36). Two 
other studies proposed that MDA5 detects the double-stranded replicative form (7.5 kbp in length) 
produced in cells infected with picornaviruses or other positive-stranded RNA viruses (51, 52). Finally, 
two independent studies reported that MDA5 assembles into long filaments along dsRNA that can be 
visualized by negative-stain electron microscopy (see figure 2). These studies also provided evidence that 
the observed filament formation relies on a cooperative binding mode of MDA5. The ability for 
cooperative filament assembly seems to be a specific hallmark of MDA5 as RIG-I is in the position to 
tightly bind dsRNA as a monomer and shows little or no cooperativity in dsRNA binding (53, 54). This 
illustrates once more the distinct but complementary role of RIG-I and MAD5 in virus recognition. 
 
1.2.2 The RD determines the specificity of RLRs for different RNA ligands 
It is known that the SF2 ATPase domain and the RD act in concert to permit proper RNA binding and 
recognition by RLRs (26, 29, 30). However, the RD is the actual domain that mediates high affinity 
binding of RLRs to their RNA ligands and also specifies this binding. Its predominant role in binding is 
expressed in the observation that the ATPase domain itself is not able to bind RNA under physiological 
conditions, whereas the RD shows high affinity for RNA also in isolation (31, 55-57). The RIG-I RD was 
firstly identified in limited proteolysis experiments and found to exhibit high affinity for 5’-ppp dsRNA
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as well as blunt-ended dsRNA determining the RD as actual sensor for these ligands (28). The subsequent 
crystal structures of the RDs of all three RLR members in complex with their RNA ligands revealed how 
binding of and specificity for different RNA patterns is achieved at the atomic level (see figure 3).
 The structure of the RIG-I RD in complex with 5’-ppp dsRNA showed how a loop rigidly caps 
the end of the dsRNA using a stacked phenyalanine while a lysine-rich basic cleft within the RIG-I RD 
sequesters the 5’-ppp group (58). The structure of the RIG-I RD in complex with blunt-ended dsRNA 
revealed that the RD binds triphosphorylated and non-phosphorylated dsRNA in significantly different 
orientations using a distinct but overlapping set of residues. Specific interactions between the 5’-ppp 
moiety and the RIG-I RD define how the RD binds 5’-ppp dsRNA, while interactions between the 
phosphodiester backbone and the RD determine how it binds blunt-ended dsRNA. In comparison to the 
5’-ppp dsRNA, the blunt-ended dsRNA swings towards the RIG-I RD in order to increase its contacts 
with the protein, whereas the conformation of the RD itself is almost identical in both complexes. This 
indicates that only slight conformational adjustments of the RIG-I RD specify the binding and recognition 
of the two RNA forms (46). 
  In case of the LGP2 RD, the blunt-ended dsRNA swings even more towards the RD and also 
rotates along its helical axis relative to the position of the blunt-ended dsRNA bound to the RIG-I RD. 
This different orientation results in a further extension of the interaction interface between the RNA and 
the LGP2 RD. In addition, the basic 5’-ppp binding cleft within the RIG-I RD becomes hydrophobic for 
LGP2 and also the loop that caps the exposed base pairs shows a slight different conformation. These 
structural distinctions determine altogether the different binding mode of the RIG-I RD and the LGP2 RD 
(31, 46, 58).  
 To date, a structure of the isolated MDA5 RD in complex with its RNA ligand is not available, 
indicating that its RNA binding capability relies to a greater degree on the presence of the SF2 ATPase 
domain than in cases of the RIG-I RD and LGP2 RD (see also section 1.3.2) (59). Indeed, the MDA5 RD 
shows the lowest RNA affinity among all three homologs (59) and crystallization of a truncated MDA5 
version containing the RD and the SF2 ATPase domain in complex with dsRNA succeeded. This 
structure revealed that the MDA5 RD recognizes the stem region of the dsRNA ligand rather than its 
ends. The loop, that the RIG-I RD uses to rigidly cap the end of the dsRNA, is disordered in the case of 
MDA5. Instead, residues on the flat surface of the MDA5 RD mediate dsRNA stem recognition. In this 
way, the MDA5 RD adds a decisive contribution to the capability of MDA5 molecules to assemble into 
filaments along dsRNA (see also section 1.3.2) (30). The comparison of the MDA5 RD and the RIG-I RD 
further reveals that the basic 5’-ppp binding cleft within the RIG-I RD becomes less basic and shows a 
outwards protrusion in MDA5, explaining why MDA5 is not able to recognize 5’-ppp moieties (58). 
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 In this sense, the RD routes the selectivity of the RLR family members for different RNA 
structures and therefore permits the detection of largely distinct groups of viruses and viral RNAs.  
 
 
 
 
Figure 3: Crystal structures of the RDs of all three RLR family members in complex with their RNA ligands. The 
RD is shown in red, the structural zinc ion in grey and the RNA ligand in black. Adapted from (30, 31, 46, 58). 
 
 
 
1.3 The structural basis for antiviral signal activation by RLRs 
A series of recent structural studies on RIG-I and MDA5 in isolation and in complex with dsRNA gave 
important mechanistic insight into the function of these RLRs. The crystal structures presented in these 
studies expand the knowledge that was gained from the structural work on the isolated RLR RDs (see 
section 1.2.2) and provide a more complete picture regarding RNA recognition, activation, regulation and 
antiviral signaling induction by RLRs. These studies also highlight structural differences between the two 
RLR family members RIG-I and MDA5 that contribute to their divergent function (see section 1.2.1). 
 
1.3.1 RIG-I is activated by a conformational switch that triggers signaling 
RIG-I is one of the first SF2 helicases that were cocrystallized with an RNA substrate. The structural 
comparison of the RNA-bound form of RIG-I with the ligand-free state revealed that RIG-I is activated 
by a conformational switch induced by the binding of the RNA (see figure 4). In absence of an RNA 
ligand, RIG-I shows a rather open and elongated conformation. The RD is supposed to be flexible and to 
move freely on the linker that connects the RD with the C-terminal RecA-like fold of the SF2 ATPase
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domain. In contrast, the CARDs are forming a rigid unit with the α-helical insertion of the ATPase core. 
Packing against the insertion region, the CARDs are only partially accessible and simultaneously block 
the RNA binding site of the insertion. In this manner, the CARDs ensure that RIG-I is kept in an inactive 
state in the absence of RNA species indicating a viral infection (60).   
 Upon binding of the RNA substrate, the RIG-I molecule undergoes a distinct conformational 
change accompanied by fundamental rearrangements of the RIG-I domains (see figure 4).  The RD and 
the SF2 ATPase domain act in concert to fully encircle the helix of the dsRNA ligand. The two RecA-like 
folds come together to create a mature dsRNA- and active ATP-binding site. The RD is not longer 
flexible, but captured in a compact ring structure, whereas the CARDs are displaced from the insertion 
region by the incoming RNA ligand. They are now fully accessible and supposed to freely move on the 
long linker situated between the CARDs and the N-terminal RecA-like fold of the SF2 ATPase domain 
(26, 29, 60).  
 The process of binding RNA appears to be highly complex as multiple sites within the RIG-I 
molecule are involved. In fact, all three subdomains of the ATPase core contribute to the binding of the 
RNA substrate. In particular, residues of the conserved motifs Ia and Ib within the N-terminal RecA-like 
fold undergo contacts with the RNA, whereas the C-terminal RecA-like fold contributes with residues of 
the motifs IV and V. These and other specific contacts are restricted to the phosphodiester backbone of 
the dsRNA and allow no sequence-specific recognition (26, 29).  
 The RD participates in this network of backbone interactions, but additionally caps the end of the 
dsRNA as previously observed (see section 1.2.2). It is supposed that the RD functions as a capture 
domain whose high affinity for RNA allows initial binding of RNA ligands. This initial binding is thought 
to increase the local concentration of dsRNA in proximity of the SF2 ATPase domain and thereby to 
facilitate the formation of the closed and active RNA clamp structure. The conformational switch, that is 
associated with this step, forces finally the release of the tandem CARDs leading to a full activation of 
RIG-I (see also section 1.4) (60). 
 The RIG-I molecule is furthermore characterized by a striking V-shaped linker that is composed 
of two long α-helices. This linker bridges the C-terminal RecA-like fold and the RD and simultaneously 
grips an α-helix that projects from the N-terminal RecA-like fold. Consequently, the V-shaped linker 
establishes extensive interactions and a mechanical connection between these three domains in the closed 
ring formation (see figure 4). The linker is for that reason assumed to facilitate the communication 
between the domains within the RNA clamp structure. It likely acts as a mechanical transmitter that 
coordinates and adjusts the relative orientations of the C- and N-terminal RecA-like fold and the RD 
during the step of RNA binding. In this way, the V-shaped linker does not only contribute to the synergy
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between the RD and the SF2 ATPase domain concerning RNA binding, but also assists in the release of 
the CARDs that represents the actual and final trigger for antiviral signaling (see also section 1.4) (26, 29, 
60). 
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Figure 4: Crystal structures of RIG-I in the inactive, ligand-free state (left) and in the active, ligand-bound form 
(right). The positions of the flexible linked RD and CARDs are just illustrated. The RD is shown in red, the CARDs 
in yellow and the three subdomains/folds of the SF2 ATPase domain are shaded in blue. The structural zinc ion is 
highlighted in grey and the dsRNA in black. Adapted from (26, 29, 60).   
 
 
1.3.2 The activation of MDA5 shows mechanistic similarities and differences to RIG-I 
In 2012, the crystallization of the MDA5 RNA clamp structure succeeded. This structure shows high 
similarity to the corresponding RIG-I RNA clamp structure concerning the overall architecture and their 
arrangement of the RD and the three subdomains of the SF2 ATPase domain (see figure 5). The RD, N- 
and C-terminal RecA-like folds, as well as the alpha-helical insertion form a closed ring that completely 
surrounds the dsRNA as already observed for RIG-I. All four units participate in the binding of the RNA 
ligand and again the contacts are limited to the phosphodiester backbone and do not allow a sequence-
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specific RNA recognition. The MDA5 and RIG-I RNA clamp structure also share the V-shaped linker 
between the RD and the C-terminal RecA-like fold that is assumed to be important for relaying 
information between the sensory RD and the catalytic/mechanical devices of the ring (N- and C-terminal 
RecA-like folds) (see section 1.3.1). All these similarities indicate that related mechanisms underlie the 
activation of MDA5 and RIG-I (30).  
 However, the MDA5 RNA clamp structure exhibits subtle differences relative to the RIG-I 
structure. These structural distinctions have significant impact on the behavior of MDA5 on the molecular 
level and determine its function. As already emphasized in section 1.2.2, the MDA5 RD recognizes the 
stem of the dsRNA ligand rather than its ends and this binding mode is influenced by the SF2 ATPase 
domain of MDA5. In detail, a specific α-helix within the insertion region positioned at the interface with 
the RD significantly differs in length between RIG-I and MDA5. This length difference is conserved 
indicating its functional importance. Within the RNA clamp structure, the longer α-helix of the RIG-I 
insertion pushes the RIG-I RD towards the bottom tip of the N-terminal RecA-like fold, which results in 
an asymmetrically closed O-shaped ring around dsRNA (see figure 5). In contrast, the shorter α-helix 
within the MDA5 insertion allows this subdomain to provide a docking site for the MDA5 RD to be 
positioned near the dsRNA stem. As a consequence, MDA5 forms a more open C-shaped ring around 
dsRNA with a gap between the MDA5 RD and the N-terminal RecA-like fold (see figure 5). Thus, the 
MDA5 insertion controls the precise positioning of the MDA5 RD for efficient recognition of the dsRNA 
stem. The stem is additionally detected by the C-terminal RecA-like fold that inserts a conserved loop 
into the major groove. These indirect and direct contributions of the MDA5 SF2 ATPase domain to 
dsRNA stem recognition provide the atomic basis that allows MDA5 molecules to cooperatively 
assemble into filaments along dsRNA (30) (see also section 1.2.1).  
 The monomeric MDA5 RNA clamp structure gives no information concerning the MDA5:MDA5 
interface and the intermolecular contacts established during filament formation on dsRNA. First structural 
insights into the cooperative assembly of MDA5 along dsRNA and were obtained by three-dimensional 
reconstruction of the filamentous MDA5 architecture employing electron microscopy. These studies 
revealed that MDA5 assembles in a head-to-tail fashion by forming extensive intermolecular contacts 
between parts of the SF2 ATPase domain, which in particular involve the N- and C-terminal RecA-like 
folds. Beyond that, the structure reconstruction of the MDA5 filament proposes a key role for the MDA5 
RD in cooperative assembly. The data suggest that the RD of one MDA5 ring invades an adjacent MDA5 
ring by contacting its insertion as well as its N-terminal RecA-like fold. Suchlike interactions would 
enable MDA5 to assemble in intertwined rings along dsRNA and hence to generate stable filaments. The 
CARDs are fully accessible within this arrangement and are supposed to form a regular array at the
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outside of the filament. This fibril form is believed to represent the fully activated state of MDA5 that 
allows efficient antiviral signaling (see section 1.4) (30, 61).  
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Figure 5: Comparison of the RIG-I and MDA5 RNA clamp structure. The RD is shown in red, the three 
subdomains/folds of the SF2 ATPase domain are shaded in blue (upper panels) or are shown in grey (lower panels). 
The structural zinc ion is highlighted in grey and the dsRNA in black. Adapted from (29, 30).     
 
 
1.3.3 The function of ATP hydrolysis in the activation of RLRs is unknown 
Despite ongoing progress in the functional understanding of RLRs, the precise role of ATP hydrolysis in 
RLR mediated antiviral signaling remains a major question. It is known that sole RNA binding by RLRs 
is insufficient to trigger signaling. MDA5 mutants are affected in their capability to hydrolyze ATP but 
still able to form filaments show a clearly reduced signaling activity in living cells (30). It is further 
known that simultaneous binding of ATP increases the affinity of RLRs for dsRNA, but the actual step 
that the hydrolysis of ATP drives in the course of RLR activation remains elusive (60). In contrast to bona 
fide helicases that use ATP to unwind nucleic acid duplexes, RIG-I is rather assumed to translocate along 
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dsRNA. This translocation activity of the receptor is supposed to contribute to antiviral signal generation 
by inducing further changes in protein conformation (62). In this sense, RIG-I and MDA5 might consume 
ATP to adopt a conformational state that allows optimal presentation of the CARDs and hence 
maintenance of active signaling (26). In another conceivable scenario, the hydrolysis of ATP might 
contribute to the tight regulation of the innate immune response by driving the cycling of RLRs between 
an inactive (RNA-unbound) and an active (RNA-bound) state. In this scenario, posttranslational 
modifications and/or protein interactions (see section 1.4.1) of the temporarily accessible CARDs finally 
trap RIG-I and MDA5 in a long-term active state as for steric reasons the modified CRADs cannot be 
rebound by the ATPase domain. After this step, the activation of downstream signaling pathways via the 
adaptor protein MAVS can finally occur (60). 
 
 
 
1.4 RIG-I and MDA5 use the adaptor MAVS to induce cytokine production 
The release or presentation of the CARDs by RNA-bound monomeric RIG-I and filamentous MDA5 is 
the actual trigger of antiviral signaling pathways. The accessible CARDs are believed to undergo 
posttranslational ubiquitination catalyzed by particular E3 ligase machineries and/or non-covalent 
interactions with specific ubiquitin species that qualify the CARDs to enter a homotypic interaction with 
the signaling adaptor protein MAVS. Subsequent polymerization of the adaptor MAVS transmits the 
signal via pathways that terminate with the activation of transcription factors operating the production of 
proinflammatory, antiviral and immunomodulating cytokines. The signaling activity of MDA5 and RIG-I 
is supposed to be regulated by the third RLR member LGP2 that is not in possession of CARDs and 
hence unable to signal by itself.  
 
1.4.1 Ubiquitin and the polymerization of MAVS propagate the antiviral signaling cascade 
One of the first events that are believed to go along with the RNA-induced release of the CARDs is their 
robust ubiquitination mediated by the K63-specific RING-finger E3 ligases TRIM25 (member of the 
tripartite motif (TRIM) protein family) and Riplet (RING finger protein leading to RIG-I activation). Both 
enzymes exhibit a PRYSPRY domain that is supposed to bind the first RIG-I CARD once it becomes 
available upon binding of RIG-I to an RNA-antagonist (see section 1.3.1). The subsequent attachment of 
K63-linked polyubiquitin chains to specific lysine residues (biochemcial studies revealed K 154, 164 and 
172 as primary targets) within the second CARD of RIG-I traps the CARDs in their accessible state (63-
66) and enhances a homotypic CARD-CARD interaction with the signaling adaptor protein MAVS
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(mitochondrial antiviral signaling protein). In an alternative scenario, TRIM25 and Riplet generate a pool 
of free K63-linked tetraubiquitin chains that interact with the CARDs of RIG-I as soon as they are 
released. This non-covalent binding of unanchored polyubiquitin chains is thought to promote an 
oligomerization of the RIG-I receptor molecules and the subsequent CARD-CARD interaction with 
MAVS (30, 66-68).  
 MAVS (also known as IPS-1, VISA or Cardif) was identified as an antiviral signaling adaptor 
protein that acts downstream of RIG-I and MDA5 in 2005. A C-terminal transmembrane domain targets 
MAVS to the outer mitochondrial membrane, whereas an N-terminal CARD allows interaction with the 
CARDs of RIG-I and MDA5 (69-73) (see figure 6). In 2011, a striking study provided evidence that  
RIG-I, in presence of K63-linked tetraubiquitin chains, supplies the initial impetus for a prion-like 
conversion of monomeric MAVS into functional, fibrillar polymers on the mitochondrial membrane. This 
conformational switch of MAVS goes along with the activation and propagation of antiviral signaling 
cascades (see section 1.4.2) (74).  
 Similar data exist for MDA5. It appears that the CARDs of MDA5 share RIG-I’s capability to 
bind unanchored K63-linked tetraubiquitin chains and that this binding is essential for MDA5 to activate 
antiviral pathways (67, 68). However, current data suggest that MDA5 CARDs possess an intrinsic 
oligomerization ability that distinct them from RIG-I CARDs (30). This specific feature and the given 
proximity of the MDA5 CARDs within RNA-bound filaments are assumed to allow those CARDs to 
form defined oligomeric patches at the outside of the filaments similar to other death-domain complexes 
(75). Oligomeric assemblies of the isolated MDA5 CARDs have been shown to be sufficient to induce 
MAVS polymerization in vitro, whereas the monomeric CARDs of RIG-I required the presence of K63-
linked tetraubiquitin chains (30). These observations imply differing roles of K63-linked ubiquitin chains 
in signaling by MDA5 and RIG-I.  
 Albeit the precise mechanism and the structural details of MAVS binding and activation by RIG-I 
and MDA5 are still unknown, it is generally accepted that the assembly of a functional MAVS 
signalosome represents a crucial step for RLRs to propagate antiviral signaling (see figure 6). 
  
1.4.2 The activated transcription factors NF-κB, IRF3 and IRF7 drive the cytokine production 
Activated MAVS is known to interact with several different downstream signaling proteins. Among these 
molecules are TRADD (tumor necrosis factor receptor type-1 associated death domain), RIP1 (receptor-
interacting serine/threonine-protein kinase 1), FADD (Fas-associated protein with death domain), TRAF6 
and TRAF3 (tumor necrosis factor receptor associated factors) (4, 66, 76, 77). All these factors form an
 I INTRODUCTION  
  17 
antiviral signaling platform that represents a branching point by mediating downstream signaling to 
IRF3/7 (interferon regulatory factors) as well as NF-κB (nuclear factor-κB).  
 TRAF3 mediates the activation of the IKK-related kinases (see NF-κB activation) TBK1 (TANK-
binding kinase 1) and IKKε (inhibitor of κB kinase ε), which are required for the phosphorylation of IRF3 
and IRF7. The dimerization of phosphorylated IRFs promote their translocation to the nucleus, where 
they upregulate the expression of type I interferons (66, 78). 
  The association of activated MAVS with TRAF6, TRADD, RIP1 and FADD is followed by the 
caspase-8/10 dependent activation of the IκB kinase (IKK) complex (4, 79). This complex, which 
comprises the two catalytic subunits IKKα and IKKβ as well as the regulatory subunit IKKγ (also known 
as NEMO (NF-κB essential modulator)), is required to mediate downstream signaling to NF-κB (80). The 
five members p65 (RelA), RelB, c-Rel, p50 and p52 of the NF-κB transcription factor family act as 
homo- or heterodimers. In unstimulated cells, regulatory IκB (inhibitor of κB) proteins sequester the NF-
κB dimers in the cytoplasm by masking their NLS (81, 82). Upon stimulation, the activated IKK complex 
phosphorylates the IκB proteins at specific serine residues. This phosphorylation primes IκB proteins for 
K48-linked polyubiquitination that results in degradation by the 26S proteasome. The released NF-κB 
dimers translocate to the nucleus, where they promote the expression of various proinflammatory 
cytokines and antimicrobial effector molecules (83, 84). 
 Type I interferons and other cytokines are rapidly induced during viral infection and are secreted 
by infected cells. The released cytokines bind distinct surface receptors on target or effector cells. This 
cytokine signaling causes activation of the transcription factor ISGF3 composed of STAT1, STAT2 
(signal transducers and activators of transcription) and IRF9 and allows transcriptional activation of a 
common set of ISGs (interferon stimulated genes). The ISG encoded proteins mediate antiviral protection 
by inhibition of the viral lifecycle and stimulatory effects that coordinate the transition to the adaptive 
immune response during infection. It is this pathway that constitutes the essential role of virus induced 
cytokines for our survival (85, 86).  
 
1.4.3 CARDless LGP2 regulates the antiviral activity of RIG-I and MDA5 
LGP2 is in the position to bind dsRNA-antagonists (31, 87), but given the absence of any CARD in LGP2 
it cannot transmit this signal. That raises the question which actual function the third RLR member adopts 
and fueled speculations regarding a regulative role of LGP2 that modulates signaling by RIG-I and 
MDA5. Indeed, several studies report an inhibitory role of LGP2 in RIG-I signaling. In these studies 
transient overexpression of LGP2 in living cells inhibited the production of type I interferons and NF-κB-
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Figure 6: Simplified illustration and schematic overview of MDA5 filament formation, MAVS activation and 
subsequent antiviral signaling pathways that can be inhibited at multiple levels by the paramyxoviral V protein 
(highlighted in orange). Adapted from (30, 53, 54, 61, 109,111, 113, 114, 130). 
 
 
dependent pathways upon Newcastle disease virus or Sendai virus infection (21, 22, 31). This prompted 
the view that LGP2 acts as a negative feedback regulator of signaling initiated by RIG-I, which is known 
to sense these paramyxoviruses (see section 1.2.1). In support of this proposed inhibitory role, LGP2 
knockout mice displayed enhanced resistance to intranasal infection by vesicular stomatitis virus, a 
negative strand virus specifically recognized by RIG-I (see section 1.2.1). In addition, the LGP2 deficient 
mice were observed to exhibit an impaired type I interferon production in response to infection by 
EMCV, a picornavirus sensed by MDA5 (see section 1.2.1). This finding implies that LGP2 contributes 
to positive regulation of MDA5 mediated antiviral signaling (88). In contrast, a study using a different 
strain of LGP2 knockout mice provided evidence that LGP2 facilitates signaling by both MDA5 and RIG-
I (19). The function of LGP2 in virus recognition and signaling still remains controversial. It has been 
suggested that LGP2 might modify virus RNA by removing viral RNA binding proteins, alter the 
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conformation of RNA, modulate the intracellular localization of or sequester viral RNA to influence the 
function of RIG-I and MDA5 (18). Many questions remain and further mechanistic studies will be 
required to resolve the precise action of LGP2 in antiviral signaling.  
 
 
 
1.5 The paramyxoviral V protein is a potent cytokine antagonist 
Viruses evolved numerous and various mechanisms to counteract the host immune response (89-97). This 
section focuses on the V protein that paramyxoviruses produce to antagonize central elements of the 
innate immune system. This protein severely disturbs the production of as well as signaling by 
immunomodulating cytokines at several levels, but also attacks the first step of viral ligand sensing by 
directly targeting MDA5.  
 
1.5.1 The V protein is a non-structural protein required for viral pathogenesis  
The V protein is a non-structural protein that is not incorporated into the virus particle (98), but rather 
represents a virulence factor (99). The V protein is expressed by the P gene of paramyxoviruses. This 
gene exhibits two alternative open reading frames that give rise to the structural P and the non-structural 
C protein. An additional RNA-editing process generates a modified mRNA that is translated into the V 
protein. As a result of the editing process, the P and the V protein share an identical N-terminal sequence 
but possess different C-termini (100, 101). The C-terminal domain (CTD) of the V protein is highly 
conserved among the family of paramyxoviruses and is known to fold into a unique zinc binding motif 
(see figure 7). In this motif, which shows homology to zinc finger motifs found in many transcription 
factors and other nucleic acid binding proteins, seven highly conserved cysteines and one histidine 
coordinate two zinc ions (100, 102-105). The less conserved N-terminal domain (NTD) of the V protein is 
assumed to be more flexible and partly unfolded. In case of the Parainfluenza virus 5 (PIV5) V protein, 
the NTD is partially stabilized by the C-terminal zinc binding motif whose two β-strands form a 
continuous β-sheet with the NTD (see figure 7A). However, the overall structure of the NTD appears to 
be very transient and is characterized by many flexible loop regions (104, 106). This intrinsic flexibility 
and structural plasticity might represent the key that allows the V protein to adapt to many different target 
proteins and hence to function as potent antagonist of the host immune response (see sections 1.5.2 and 
4.4). 
 In 1997, a study using a modified Sendai virus strain unable to produce the V protein showed that 
this protein is not essential for the replication cycle of the virus per se, but maintains viral replication in 
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later stages of infection. These results suggested a critical role of the V protein in viral pathogenicity (99).  
Five years later, two studies revealed the V protein as potent interferon antagonist that inhibits both the 
induction of type I interferons as well as interferon signaling (107, 108) . Many mechanistic studies 
followed and identified several specific targets of the V protein that function at different levels of innate 
immune pathways (see figure 6).   
                                                                                                                                 
SV5 V
PIV5 V protein
(in complex with DDB1)
CTD
NTD
NTD
CTD
β1
β2
A
B
 
 
Figure 7: (A) Crystal structure of the Parainfluenza virus 5 (PIV5) V protein in complex with DDB1 (DNA 
damage-binding protein 1, not shown here). The N-terminal domain (NTD) is shown in grey. The conserved zinc 
binding motif of the C-terminal domain (CTD) is highlighted in orange and its two bound zinc ions are shown in 
grey. Adapted from (104). (B) Structure-based alignment of the conserved CTD of selected paramyxoviral V 
proteins with annotated secondary structure elements. Residue conservation is color-coded according to percentage 
identity. The highly conserved histidine and cysteine residues, which coordinate the two zinc ions within the CTD, 
are highlighted in orange.  
 
 
1.5.2 The V protein sabotages the innate immune response at several levels 
Inhibition of innate immune signaling cascades by paramyxoviral V proteins at the transcriptional level 
has been addressed in several studies (see also figure 6). Transcription factors of the NF-κB family 
usually function as p65/p50 heterodimers. The Measles Virus (MV) V protein has been shown to bind the 
p65 subunit and to prevent its nuclear translocation. In this way, the V protein is able to suppress 
p65/p50-mediated NF-kB activity and to impair NF-κB-dependent gene expression (109). Similar results 
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have been reported for the transcription factor IRF3. The binding of V proteins of different 
paramyxovirus family members to IRF3 has been revealed to retain the transcription factor in the cytosol 
(110, 111). Moreover, the V protein is assumed to induce degradation of IRF3 (112). Another study 
reported binding and transcriptional inactivation of IRF7 by MV V protein indicating that this 
transcription factor represents an alternative target of paramyxoviral V proteins (113).  
 At the level of activating kinases, the paramyxoviral V protein has been revealed to inhibit 
IRF3/IRF7 activation in an indirect manner by acting as a decoy substrate of IKKε/TBK1 (114). V 
proteins are directly phosphorylated by this IRF3/7 kinase. Thus, V proteins are proposed to interfere with 
IRF3/7 phosphorylation by mimicking and competing out IRF3/7 as IKKε/TBK1 substrates.  
 NF-κB, IRF3/7 and IKKε/TBK1 represent targets that are essential for cytokine induction (see 
section 1.4.2). But the inhibition by paramyxoviral V proteins goes beyond this and also affects signal 
transduction by cytokines. The transcription regulators STAT1 and STAT2 are key components of the 
paracrine and autocrine cytokine signaling system (see section 1.4.2) and are subjected to direct and 
indirect inhibition by V proteins. The V proteins of Nipah virus, Hendra virus as well as MV are known 
to bind and sequester STAT1 and STAT2 in the cytoplasm to prevent their nuclear accumulation. The 
MV V protein has been shown to bind in addition the third member IRF9 of the ISG3 complex. The 
Nipah virus V protein inhibits cellular response to cytokines also by preventing activating tyrosine 
phosphorylation of STAT proteins, while the MV V protein is not able to interfere with this step (115-
117). In contrast to these direct inhibition strategies, many paramyxoviruses have evolved indirect 
mechanisms to disturb signaling by STAT proteins including the proteasomal degradation of these 
proteins. Mumps virus, PIV5 and human PIV2 use their V protein to recruit STAT1, STAT2, Cul4A 
(cullin RING ubiquitin ligase 4A) and its substrate recruiting adaptor protein DDB1 (DNA-damage-
binding protein-1) to assemble STAT-degradation complexes (also called VDCs = V protein dependent 
degradation complexes). The DDB1-Cul4A ubiquitin ligase machinery is usually involved in the 
regulation of DNA repair, DNA replication and transcription. Binding of the V protein to DDB1 
manipulates the substrate specificity of the ubiquitin ligase complex and trains it for STAT-degradation 
(104, 118-126) (see also section 4.4).  
 The numerous studies investigating STAT inhibition by paramyxoviruses demonstrate its 
functional diversity and have taught us that the mechanistic details of V protein-dependent evasion 
strategies can highly depend on the virus species and its host (95, 127-129).                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   
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1.5.3 The V protein specifically binds and inhibits MDA5 
Beside MDA5, many other immune receptors (e.g. RIG-I, TLR 3, 4, 7 and 8) use IKKα/IKKβ or 
IKKε/TBK1 as terminal kinases to activate NF-κB or IRF transcription factors. Paramyxoviral V proteins 
have the potential to inhibit all these signaling pathways by targeting most of these shared key 
components. In addition, paramyxoviruses are in the position to specifically and severely affect the 
MDA5 signaling cascade at the very first step by targeting MDA5 itself. The direct inhibition of MDA5 
by paramyxoviral V proteins was firstly described in 2004 (130). This initial study revealed that V 
proteins of different paramyxoviruses prevent the activation of both NF-κB and IRF3/7 by binding to 
MDA5. Further characterization of this interaction showed that the conserved zinc binding motif of the 
CTD shared by paramyxoviral V proteins (see section 1.5.1) is sufficient to mediate MDA5 binding and 
requires structural integrity of this motif (110, 131-133). A subsequent study investigating a wide variety 
of 13 paramyxoviruses (namely PIV5, human PIV2, porcine rotavirus (PoRV), Newcastle disease virus 
(NDV), mumps, measles, Menangle, Hendra, Nipah, Mapuera, Sendai, Salem and Tioman virus) showed 
that all tested V proteins target MDA5 via their conserved cysteine-rich CTD in a direct mode (134). 
Despite the high sequence similarity between RLR family members, the tested V proteins were found to 
fail at binding of RIG-I, but were able to interact with LGP2 (134-136). Detailed mapping of the 
interaction sites identified the C-terminal RecA-like fold within the ATPase domain of MDA5 and LGP2 
as common target region for paramyxoviral V proteins (135, 136). In addition, some paramyxovirus V 
proteins are able to target further regions of MDA5, which include for instance the N-terminal RecA-like 
fold (136). In contrast to these virus specific interactions, the binding involving the conserved CTD of V 
proteins and the C-terminal RecA-like fold of MDA5 (and LGP2) appears to be universal. The described 
data point toward a conserved interaction interface that allows paramyxoviruses to specifically inhibit 
MDA5, but not RIG-I signaling initiation.  
 In vitro experiments that investigated the impact of V protein binding on MDA5 function 
demonstrated that V protein interaction affects ATP hydrolysis mediated by MDA5. Titration of purified 
V protein into a solution containing purified and functional MDA5 was shown to cause a complete 
shutdown of the MDA5 ATP hydrolysis activity (see figure 8) (57, 135, 137). Reports regarding the 
interference of V protein interaction with MDA5 RNA binding activity are contradicting. A study 
proposing that V proteins block the RNA binding capability of the MDA5 ATPase domain (136) is in 
opposition to data showing that V protein interaction does not interfere with RNA binding by MDA5 
(137). However, no study provided evidence that paramyxoviral V proteins are able to disturb the 
cooperative filament assembly of MDA5 along dsRNA. 
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Figure 8: In vitro experiment demonstrating the dose-dependent shutdown of MDA5 ATP hydrolysis activity by the 
paramyxoviral V protein (57, 137). 
 
 
1.6 Objectives 
The aim of this work was the crystallization of a complex between MDA5 and the paramyxoviral V 
protein to derive a first molecular mechanism of viral interference with RLRs. Structural determination of 
this complex was assumed to provide important mechanistic details regarding recognition and inhibition 
of MDA5 by paramyxoviral V proteins. The identification of the C-terminal RecA-like fold as common 
target site for V proteins (135,136) (see section 1.5.3) implies the possibility that V protein interaction 
might interfere with the formation of a mature dsRNA- and active ATP-binding site upon ligand 
recognition by MDA5 (see sections 1.3.1 and 1.3.2). Structural investigation of the viral inhibitor protein 
bound to its target MDA5 was expected to reveal how exactly the V protein affects the ATPase activity of 
MDA5 and to answer the question whether and in what manner the V protein interferes with the 
cooperative RNA binding mode of MDA5. These questions address major aspects as both, ATPase 
activity as well as proper RNA binding, have been shown to be crucial for antiviral signal propagation by 
MDA5 (30) (see section 1.3.3). Structural knowledge at the atomic level and the deduction of a 
mechanistic inhibition model were assumed to pave the way for precise and verifying biochemical studies 
examining the impact of V protein binding on the function of MDA as viral RNA receptor. Moreover, the 
detailed determination of the interaction interface between MDA5 and the V protein was assumed to 
explain, why the inhibitor protein specifically recognizes and binds the two RLR family members MDA5 
and LGP2, whereas the highly related RIG-I molecule is able to evade V protein binding. To this end, 
structural analysis of the MDA5:V protein complex was expected to contribute to our general 
understanding of RLR function and to give significant insights into virus-host interactions and viral 
immune evasion strategies.  
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2. Materials and Methods 
 
2.1 Materials 
All chemicals used in this work were of the highest available grade obtained from Roth, Merck or Sigma-
Aldrich, unless otherwise stated. Oligonucleotide primers for polymerase chain reaction (PCR) were 
obtained in “high purity salt free” (HPSF®) form from Metabion or Biomers. Enzymes for molecular 
biology were obtained from New England Biolabs and Stratagene. Crystallization screens and tools were 
from Hampton Research, NeXtal (QIAGEN) and Jena Bioscience. Electrophoretic mobility shift assays 
were performed with HPLC-grade RNA oligonucleotides from biomers. Synthetic poly(I:C) RNA was 
purchased from Sigma-Aldrich for activity assays and from The Midland Certified Reagent Company for 
negative-stain electron microscopy.  
 
2.2 Methods   
The sections 2.2.1 and 2.2.2 list basic methods employed throughout the work. Further methods are stated 
in chronological order according to their declaration in chapter 3.  
 
2.2.1 General molecular biology methods  
 
2.2.1.1 Cloning 
DNA fragments encoding the desired protein constructs were amplified from plasmids or cDNA 
containing the sequence of interest using the Phusion High-Fidelity Master Mix (New England Biolabs) 
and standard oligonucleotide primers (Metabion). Amplified DNA fragments were purified from 
preparative agarose gels using the NucleoSpin Gel and PCR Clean-up kit from Macherey-Nagle and 
subjected to restriction enzyme (New England Biolabs) digest. Ligation reactions of digested and purified 
insert DNA with vector DNA were performed with T4 DNA Ligase (New England Biolabs) and 
incubated for 1 h at room temperature. Subsequent transformation of Escherichia coli XL1-Blue (K12) 
was performed as described in section 2.2.1.3. All cloned constructs were verified by DNA sequencing. 
 
2.2.1.2 Site-directed mutagenesis 
PCR for site-directed mutagenesis was performed using the Pfu Ultra DNA Polymerase (Stratagene) and 
standard oligonucleotide primers (Biomers). (Dam)-methylated, non-mutated template DNA was digested 
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by 20 U DpnI (New England Biolabs) for 2 h at 37°C. Subsequent transformation of Escherichia coli 
XL1-Blue (K12) was performed as described in section 2.2.1.3. All mutants described in this work were 
generated by this standard protocol and constructs were verified by DNA sequencing.  
 
2.2.1.3 Heat shock transformation of Escherichia coli XL1-Blue (K12) 
Chemically competent Escherichia coli XL1-Blue (K12) cells were mixed with plasmid DNA and 
incubated for 20 min on ice. After heat-shocking for 2 min at 42°C, the cells were incubated for 1 min on 
ice. The cells were supplemented with 1 ml LB-medium and allowed to grow for 45 min at 37°C before 
spreading on LB-plates containing the appropriate antibiotic for selection.  
 
2.2.1.4 Isolation of plasmid DNA from Escherichia coli XL1-Blue (K12) 
Single colonies were picked and inoculated into 4 ml LB-media supplemented with the appropriate 
antibiotic (see table 1). The cultures were allowed to grow overnight at 37°C and 190 rpm and harvested 
the next day by centrifugation (5000 g for 5 min). Plasmid DNA was isolated using the NucleoSpin 
Plasmid Qick Pure kit from Macherey-Nagel according to the instructions of the manufacturer.  
 
2.2.1.5 Determination of nucleic acid and protein concentrations 
Nucleic acid and protein concentrations were quantified using the Thermo Scientific NanoDrop™ 1000 
Spectrophotometer (PeqLab). The measured protein absorbance at 280 nm was adjusted using the molar 
extinction coefficient for the corresponding amino acid sequence calculated by ExPASy.  
 
2.2.2 General bioinformatics methods  
 
2.2.2.1 Protein sequence alignments and secondary structure predictions  
Multiple protein sequence alignments were built with Jalview/Muscle. Protein secondary structures were 
predicted based on sequence alignments with Jalview/JNet.  
 
2.2.2.2 Structure visualization and analysis 
Visualization and analysis (e.g. three-dimensional superposition, distance measurements, analysis of 
flexible and unstructured protein regions or crystal contacts) of structures were achieved with PyMol.  
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2.2.3 Small scale protein testexpression 
Escherichia coli Rosetta (DE3) cells (Novagen) were transformed with the desired plasmid DNA 
according to the protocol described in 2.2.1.3 and allowed to grow overnight at 37°C and 190 rpm in LB-
media supplemented with antbitiotic(s) for selection (see table 1). The overnight pre-culture was 
inoculated in a ratio of 1:100 into 60 ml LB-medium containing the appropriate antibiotic(s). Small scale 
testexpression cultures were incubated overnight at defined test conditions (induction of gene expression 
with either 0.5 mM or 0.1 mM IPTG (final concentration) at OD600 and 20°C) and harvested by 
centrifugation (5000 g for 5 min). The bacterial pellets were suspended in 5 ml suitable lysisbuffer (see 
section 2.2.5 and table 3) that contained 1 mg/ml lysozyme.  After 20  min incubation on ice, the samples 
were additionally sonicated at 4°C using a Branson Sonifier 250 (2x 30 s at an intensity of 80% and at an 
output power level of 2) to ensure complete bacterial cell lysis. To permit identification of non-soluble 
protein fractions, a 5 µl aliquot of the disrupted cells was taken and mixed with SDS containing protein 
loading buffer for later analysis. The remaining sample was centrifuged for 30 min at 48 000 g and 4°C. 
To permit later analysis of soluble protein fractions, a 5 µl aliquot of the supernatant was taken and mixed 
with SDS containing protein loading buffer. Glutathione-coated cellulose beads (Roth) or Ni-NTA 
agarose beads (Macherey-Nagel) were equilibrated with washingbuffer (lysisbuffer without lysozyme, see 
section 2.2.5 and table 3) and a 1:1 bead suspension was prepared. 50 µl of the bead suspension was 
added to 1 ml of the supernatant and the samples were incubated for 1 h at 4°C on a rotating wheel. The 
beads were washed four times with 1 ml washingbuffer. To elute protein from beads, the bead fraction 
was mixed with SDS-containing protein loading buffer and incubated together with the previously taken 
samples of disrupted cells and supernatant for 10 min at 90°C. To separate beads from eluted proteins, the 
samples were centrifuged for 1 min at 16 000 g. The samples (1 µl of disrupted cells and supernatant 
respectively, 5 µl of bead eluate) were loaded on a 15% SDS-polyacrylamide gel and proteins were 
separated by electrophoresis according to Laemmli. Coomassie staining of the gel allowed analysis of 
protein yield and solubility.  
 
Table 1: Antibiotic stock solutions (used in 1:1000 dilution). 
Antibiotic Concentration Solvent 
Ampicilin (Na-salt) 100 mg/ml water 
Kanamycin 50 mg/ml water 
Chloramphenicol 50 mg/ml ethanol 
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2.2.4 Large scale protein expression  
Sequences encoding full length mmMDA5 (1-1025aa) and ggMDA5 (4-1001aa) were cloned into a 
modified pET-28a(+) vector (Novagen) carrying a TEV cleavage site. Sequences encoding the SF2 
ATPase domain of hsMDA5 (304-890aa), mmMDA5 (305-890aa), ssMDA5 (303-887aa), btMDA5 (303-
885aa), ggMDA5 (297-864aa) and tgMDA5 (363-935aa), the RDless version of mmMDA5 (1-890) and 
the CARDless version of hsMDA5 (304-1017) were cloned into the pET-21a(+) vector (Novagen). The 
oligonucleotides used for cloning of these MDA5 constructs are listed in table 2. A modified pGEX 
vector containing the sequence of full-length parainfluenza virus 5 (PIV5) V protein was received from 
Ning Zheng (University of Washington). According to the testexpression results, expression of all 
constructs was carried out in Escherichia coli Rosetta (DE3) (Novagen) overnight at 20°C by induction 
with 0.1 mM IPTG. The cultures were harvested by centrifugation (5000 g for 15 min) and the bacterial 
pellets were frozen at -80°C.  
 
Table 2: Oligonucleotide list – MDA5 constructs. 
Primer name 5’-3’ sequence 
pET28 mmMDA5 M1 NheI forward catggctagcatgtcgattgtctgttctgca 
pET28 mmMDA5 D1025 BamHI reverse gcgggatccttaatcttcatcactatacaagcagt 
pET28 ggMDA5 E4 NheI forward catggctagcgagtgccgagacgagcgc 
pET28 ggMDA5 D1001HindIII reverse gtacaagcttttaatcttcatcacttgaaggacaat 
pET21 hsMDA5 P304 NheI forward catggctagcccagaactccagctcaggc 
pET21 hsMDA5 R890 XhoI reverse catgctcgagtctcttggttttcattttcttttc 
pET21 mmMDA5 P305 NheI forward catggctagcccagaactgcagctcaggc 
pET21 mmMDA5 R890 NotI reverse aaggaaaaaagcggccgctcttttgactttcattttcttttcc 
pET21 ssMDA5 P303 NheI forward catggctagcccagagctgcatctcaggc 
pET21 ssMDA5 R887 XhoI reverse catgctcgagtctcttgattttcattttcttttcca 
pET21 btMDA5 P303 NheI forward catggctagcccagagctgaatctcaggcc 
pET21 btMDA5 R885 XhoI reverse catgctcgagtctcttggttttcattttcttttcc 
pET21 ggMDA5 P297 NheI forward catggctagcccagatctcaccctgagaga 
pET21 ggMDA5 R864 SalI reverse cagtgtcgactctctttgccttcatttgtttttc 
pET21 tgMDA5 P363 NheI forward catggctagcccagatctgaccctgagagat 
pET21 tgMDA5 R935 SalI reverse cagtgtcgactctcatcaccttcatttgtttttcc 
pET21 mmMDA5 M1 NheI forward catggctagcatgtcgattgtctgttctgca 
pET21 mmMDA5 R890 NotI reverse aaggaaaaaagcggccgctcttttgactttcattttcttttcc 
pET21 hsMDA5 P304 NheI forward catggctagcccagaactccagctcaggc 
pET21 hsMDA5 E1017 XhoI reverse catgctcgagttctgaatagtcaagattgggaa 
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2.2.5 Large scale purification of MDA5 and PIV5 V proteins and their complexes 
Full length and RDless MDA5 proteins were purified by nickel affinity chromatography (Ni-NTA 
agarose beads, Macherey-Nagel), anion-exchange chromatography (HiTrap Q HP column, GE 
Healthcare) and final size exclusion chromatography (Superdex200 26/60 or 16/60 column, GE 
Healthcare). A similar protocol was used for the purification of MDA5 ATPase domains and CARDless 
hsMDA5, but cation-exchange (HiTrap S HP column, GE Healthcare) instead of anion-exchange 
chromatography was performed. Ahead of size exclusion chromatography, CARDless hsMDA5 was 
additionally cleaned via a heparin column (HiTrap Heparin HP, GE Healthcare). The PIV5 V protein was 
batch-purified using glutathione-coated cellulose beads (Roth). The GST-tag of the construct was 
removed by on-beads-cleavage using His6-tagged TEV-protease. The TEV protease was rebound to Ni-
NTA agarose beads and further purification of the PIV5 V protein was achieved by size exclusion 
chromatography (GE Healthcare, Superdex75 26/60). For complex formation, proteins were mixed in a 
1:1.5 molar ratio (MDA5/PIV5 V protein) in a final complex buffer (see table 3) and incubated for 1 h on 
ice. A stoichiometric 1:1 complex was subsequently purified by size exclusion chromatography 
(Superdex200 26/60 or 16/60 column, GE Healthcare). Lysis of bacterial cells was achieved with a 
Branson Sonifier 250 (2x 1 min at an intensity of 40% and at an output power level of 8) at 4°C. The 
purification steps were performed on the Äkta FPLC, Äkta basic or Äkta purifier system (GE Healthcare). 
Table 3 lists and states all buffers used for the different purification steps. Purification of the protein was 
monitored at all steps by SDS-PAGE according to Laemmli and Coomassie staining. Concentration of 
protein solutions was achieved with Amicon Ultra Centrifugal Cellulose Filters (Millipore).   
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Table 3: Protein purification buffers. 
Buffer Composition final pH 
Lysisbuffer 
Ni-NTA affinity chromatography 
500 mM NaCl, 50 mM Tris, 20 mM imidazole, 2 mM MgCl2,           
10 µM ZnCl2, 10 mM β-mercaptoethanol 
7.8 
Lysisbuffer 
Glutathione affinity chromatography 
500 mM NaCl, 50 mM Tris, 10 µM ZnCl2,  
10 mM β-mercaptoethanol 
7.8 
Washingbuffer 
Ni-NTA affinity chromatography 
100 mM NaCl, 50 mM Tris or Bis-Tris, 20 mM imidazole,                  
2 mM MgCl2, 10 µM ZnCl2, 10 mM β-mercaptoethanol 
8.5 or 6.5 
Washingbuffer 
Glutathione affinity chromatography 
150 mM NaCl, 50 mM Tris, 10 µM ZnCl2,  
10 mM β-mercaptoethanol 
7.8 
Elutionbuffer 
Ni-NTA affinity chromatography 
100 mM NaCl, 50 mM Tris or Bis-Tris, 200 mM imidazole,                  
2 mM MgCl2, 10 µM ZnCl2, 10 mM β-mercaptoethanol 
8.5 or 6.5 
Low salt buffer 
Anion-exchange chromatography 
100 mM NaCl, 50 mM Tris, 2 mM MgCl2, 10 µM ZnCl2,                  
10 mM β-mercaptoethanol 
8.5  
High salt buffer 
Anion-exchange chromatography 
1 M NaCl, 50 mM Tris, 2 mM MgCl2, 10 µM ZnCl2,                          
10 mM β-mercaptoethanol 
8.5  
Low salt buffer 
Cation-exchange chromatography 
100 mM NaCl, 50 mM Bis-Tris, 2 mM MgCl2, 10 µM ZnCl2,                  
10 mM β-mercaptoethanol 
6.5  
High salt buffer 
Cation-exchange chromatography 
1 M NaCl, 50 mM Bis-Tris, 2 mM MgCl2, 10 µM ZnCl2,                          
10 mM β-mercaptoethanol 
6.5  
Size exclusion chromatography buffer         
PIV5 V protein 
150 mM NaCl, 20 mM Tris, 10 µM ZnCl2,  
5 mM DTT 
7.8 
Size exclusion chromatography buffer         
MDA5 and complex formation 
150 mM NaCl, 20 mM Tris, 5 mM MgCl2, 10 µM ZnCl2,  
5 mM DTT 
7.8 
 
2.2.6 ATPase assays 
ATPase assays were performed in a 10 μl reaction volume containing 100 mM Tris pH 7.9, 150 mM 
NaCl, 5 mM MgCl2, 5 µM ZnCl2, 1 mM DTT, 0.1 mM ATP, 20 nM γ-
32
P-ATP (3000 Ci/mmol, 
Hartmann Analytic) and 50 nM poly(I:C) RNA (Sigma-Aldrich). After equilibration to 37°C, the reaction 
was started by addition of purified mmMDA5 (final concentrations 1µM, 2.5 µM, 5 µM, 10 µM and 15 
µM). After 20 min incubation at 37°C, 1 µl of the reaction mix was spotted onto a thin layer 
chromatography polyethyleneimine cellulose plate (Merck). The TLC plate was developed in 0.5 M LiCl 
/ 1.0 M formic acid and subsequently air-dried. The amount of educt (ATP) and product (liberated γ-32P) 
was visualized with a phosphorimager (GE Healthcare).  
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2.2.7 Static light scattering (SLS) measurements 
Static light scattering represents a method to determine the absolute molar mass of a protein in solution 
and permits therefore the detection of multimeric states in solution. Static light scattering is different from 
dynamic light scattering which allows the calculation of the hydrodynamic radius of a molecule from its 
diffusion coefficient. The principle of static light scattering is based on the induction of an oscillating 
dipole within a macromolecule when monochromatic laser light impinges on it, resulting in re-radiation 
of light. The intensity of this scattered light depends among other factors (e.g. polarizability of the 
molecule/strength of the induced dipole) on the concentration of the macromolecule in solution in a 
proportional manner. The intensity measurement of the scattered light allows not only the concentration 
determination of a macromolecule in solution. It also provides information whether a macromolecule 
adopts a multimeric or monomeric state in solution given the direct proportionality of the light intensity to 
the molar mass of the scattering molecule. Scattered light originating from protein monomers is 
characterized by incoherence, because the random Brownian motion of the monomers separated by 
solvent molecules induces randomness in the phase of the radiated light. In case of dimer formation two 
monomers of the protein move together in solution which results in a defined phase relationship of the 
light scattered by the two linked monomers and for this reason in coherence. This effect doubles the 
intensity of the radiated light, although the concentration of the protein solution is not changed. In this 
way static light scattering represents a technique to determine the presence of higher multimeric states of 
a given protein or the stoichiometry of a protein complex in solution.  
 Static light scattering measurements were performed by Claire Basquin (biophysics facility, Max 
Planck Institute of Biochemistry, Martinsried). A Superdex200 10/300 column (GE Healthcare) was 
connected in-line with the following detectors:  
1. UV-detector (monitor UV 900 as part of the ÄKTA purifier, wavelengths: 230 nm, 260 nm and 
280 nm). 
2. Light scattering detector (miniDAWN Treos, Wyatt Technology; allows multiangle static laser 
light scattering; possesses three detectors (at 45°, 90° and 135°) which measures the relative 
intensity of scattered light as a function of the angle between the detector and the incident laser 
beam direction). 
3. Refractive index detector (OPTILAB rEX, Wyatt Technology; determines sample mass 
concentration by measuring the refractive index difference between the sample solution and the 
reference fluid by utilizing an array of 512 photodetectors). 
The system was equilibrated with complex formation buffer (see table 3). Approximately 300 µM 
purified protein was applied on the Superdex200 10/300 column and static light scattering measurements 
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were performed at a flow rate of  0.4 ml/min. UV absorption was monitored by the Unicorn software and 
the molecular weight was determined by the AstraV software provided by Wyatt Technology.  
 
2.2.8 Small-angle X-ray scattering (SAXS) of protein solutions 
This X-ray scattering technique measures the distribution of intramolecular distances in macromolecules 
in solution and is therefore able to provide information about the shape and size of non-crystalline 
proteins in a buffer of choice. SAXS has no limitation regarding the protein size that can be studied, but 
the structures obtained by ab initio modeling are of relatively low resolution (maximum 15Å). However, 
the pair distance distribution function, which describes the paired set of all distances between all electrons 
within a protein, represents a powerful tool to detect conformational changes within a protein in solution. 
The blue curve in figure 9 shows a symmetric and parabolically shaped distance distribution function 
characteristic of a globular and compact protein with one single major center of mass. This shape is lost in 
case of a protein whose conformation is defined by more than one large center of mass (red curve in 
figure 9). 
 SAXS data were collected at EMBL beamline X33 (DESY, Hamburg, Germany). Protein 
samples after size exclusion chromatography in three different concentrations (2 mg/ml, 5 mg/ml and 10 
mg/ml) and the running buffer were used for data collection of protein and buffer, respectively. The 
buffer-corrected scattering curves showed no signs of aggregation and were processed using PRIMUS 
from the ATSAS package (138) as described. A set of 16 independent ab initio models was calculated 
using GASBOR/DAMMIF (139, 140). Conversion of the final beadmodels obtained by DAMAVER 
averaging (141) into electron density shapes was done using SITUS (142). All figures were prepared with 
UCSF Chimera. 
 
 
Figure 9: Pair distance distribution functions of a globular and compact protein with one major centre of mass (blue 
curve) and of a protein with at least two large centres of mass (red curve) (26).   
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2.2.9 Reductive methylation 
MDA5 purification was performed according to the protocols described in 2.2.5, but the final size 
exclusion chromatography buffer contained 20 mM HEPES instead of Tris. Purified MDA5 proteins were 
reductively methylated according to a standard protocol (143). After complete methylation, a second 
gelfiltration step was performed to remove reaction contaminants and a third gel filtration step to form a 
complex between reductively methylated MDA5 and purified PIV5 V protein (see section 2.2.5).  
 
2.2.10 Large scale purification of Fab fragments and triple complex formation 
Monoclonal antibodies recognizing MDA5 or the PIV5 V protein were produced in collaboration with Dr. 
Elisabeth Kremmer (Institute for Molecular Immunology, Helmholtz Centre Munich). Purified PIV5 V 
protein, full length mmMDA5 or ggMDA5 were used as antigens for the immunization of mice. 
Hybridoma cell lines, which produce IgG antibodies able to recognize epitopes of the antigen, were 
identified and preselected by the laboratory of Dr. Elisabeth Kremmer. The supernatants of the positively 
tested hybridoma cell lines were used for pulldown assays (performed with protein G beads) to select high 
affinity binders that do not interfere with the complex formation between MDA5 and PIV5 V protein. 
Large scale production and HPLC purification of the selected antibodies expressed by the hybridoma 
clones GGS/M 4A9, GGS/M 12G5, GGSV 12C10 and GGSV 16B5 was performed by the laboratory of 
Dr. Elisabeth Kremmer. The purified IgG antibodies were provided in 1x PBS pH 7.0 and fragmentation 
was performed at a concentration of 20 mg/ml using immobilized papain cross-linked to agarose beads 
(Thermo Scientific) according to the instructions of the manufacturer. Fab and Fc fragments were 
separated by size exclusion chromatography (Superdex200 16/60 column, GE Healthcare) using 1x PBS 
pH 7.5 as running buffer. The isolated Fab fragments were concentrated and added in molar excess to 
purified MDA5:PIV5 V protein complexes. After 1 h incubation on ice,  a stable triple complex 
containing MDA5, PIV5 V and Fab protein in a 1:1:1 stoichiometry was separated from free Fab 
fragments by size exclusion chromatography using complex formation buffer (see table 3) supplemented 
with 0.5 mM DTT (to ensure stability of MDA5 proteins) as running buffer.  
 
2.2.11 Crystallization of the ssMDA5:PIV5 V protein core complex 
For crystallization, residues 641-665 of the ssMDA5 SF2 ATPase domain construct and residues 55-79 of 
the PIV5 V protein construct (see section 2.2.4) were replaced with SGSGS and GSGSGSGSGS, 
respectively. Complex formation of both proteins was performed as described and freshly purified 
complex was directly used for crystallization. Crystals were obtained by an in-drop proteolysis approach. 
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To purified complex (10 mg/ml) 1:1000 (w/w) 1mg/ml trypsin (purchased from calbiochem and dissolved 
in 1mM HCl and 2 mM CaCl2) was added and the mixture was crystallized by sitting-drop vapour 
diffusion in crystallization solution (100 mM Hepes pH 7.5, 20% (w/v) PEG 1500). Crystals appeared 
within 1 day at 20°C. Crystals of selenomethionine-substituted ssMDA5 protein (expressed in Rosetta 
B834 (DE3) (Novagen) and  SelenoMet
TM
 Medium plus Nutrient Mix (Molecular Dimensions)) in 
complex with unlabeled PIV5 V protein were obtained by streak seeding using native crystal material and 
hanging-drop vapour diffusion (100 mM Hepes pH 7.5, 18% (w/v) PEG 1500). Crystals were 
cryoprotected by soaking of the crystals in 20 % 2,3-butanediol in crystallization solution and flash-
frozen in liquid nitrogen.  
 
2.2.12 Structure determination 
2.2.12.1 Principles of X-ray structure analysis 
X-ray crystallography allows the structure determination of macromolecules such as proteins at the 
atomic level. The crystal (in this case a protein crystal) rotating in an incident X-ray beam functions as a 
diffractor and the diffracted X-rays are recorded as reflections. Each diffracted X-ray results in one 
reflection and all recorded reflections together create a unique diffraction pattern in a three-dimensional 
space called the “reciprocal space”.  In this reciprocal space the location of each reflection is defined by 
three indices h,k and l representing three-dimensional coordinates.  
 The reciprocal space stands vis-à-vis a second coordinate system that is represented by the unit 
cell of the crystal and termed real space. A crystalline lattice is built up by the repeating arrangement of 
equal unit cells in which an atom’s position is given by the fractional coordinates x,y and z. Each single 
reflection in the reciprocal space can be ascribed to the diffractive contributions from all atoms in the unit 
cell. Each diffracted X-ray recorded as a reflection hkl can therefore be described as the sum of multiple 
wave equations (one equation for each diffractive contributor in the unit cell). The computed sum for a 
given reflection hkl is called the structure factor Fhkl.                                                                                
 The actual diffractors in the unit cells are not the atoms but their clouds of electrons. An X-ray 
impinging on an electron forces the electron to oscillate in the same frequency as the incoming X-ray 
wave. This causes an emission of scattered X-rays of identical wavelength in all directions of space. The 
amplitude of the scattered waves is determined by two parameters, the number of electrons and the 
scattering angle. This type of scattering is known as normal scattering and also called elastic scattering, 
Thomson scattering or scattering without energy loss.   
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 The recorded diffraction pattern should therefore contain the information of the electron density 
distribution of the molecules in the crystal. The electron density ρ at every position x,y,z in the unit cell is 
given by following equation: 
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p (x,y,z)  = electron density at position x,y,z                    α  = phase angle α of the reflection hkl                
V = volume of the unit cell    e = Euler’s number   
|Fhkl|= structure factor amplitude of the reflection hkl          i = imaginary unit  
   
 This function connects the reciprocal space of the recorded diffraction pattern with the electron 
density of the molecules in the real space via the structure factor Fhkl. The graph of this function is the 
contour map of the electron density of the molecules within the unit cell. The goal is to obtain all 
unknowns of this equation to compute the electron density map of the desired molecule.  
 Representing a wave equation, the structure factor Fhkl has to specify three parameters: frequency, 
amplitude and phase. The recorded diffraction pattern exhibits solely the intensity Ihkl for each reflection 
hkl, but can be used for the calculation of the structure factor amplitude |Fhkl| which is proportional to the 
square root of the measured intensity Ihkl. The frequency of the emitted X-rays is identical with the 
frequency of the impinging X-ray beam in case of normal scattering. The inverse connection between the 
reflection distances on the detector and the unit cell dimensions allows the determination of the unit cell 
volume V in equation (1) from reflection spacings. The only additional information that is required is the 
phase angle α, whereby each reflection hkl has its own specific phase. The information of the phase angle 
is lost during the diffraction experiment and has to be obtained in another way. Several possibilities exist 
to solve the phase problem (= phasing):   
 direct solution of the Patterson map (in case of small molecules up to approximately 1000 atoms 
and high resolution) 
 isomorphous replacement (single isomorphic replacement (SIR) or multiple isomorphic 
replacement (MIR) by e.g. soaking heavy metal ions into a crystal (= generating a heavy metal 
derivative)) 
 anomalous dispersion (single wavelength anomalous dispersion (SAD) or multiple wavelength 
anomalous dispersion (MAD) by using e.g. Se-methionine substituted protein crystals) 
 any combination of the previous methods such as SIRAS or MIRAS (SIR and MIR with 
anomalous scattering)  
 molecular replacement (MR) by utilizing a homologous searching model  
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2.2.12.2 Principles of SAD phasing   
Normal scattering or elastic scattering results in the so called Friedel’s law stating that members of a 
Friedel pair of reflections have equal amplitude and opposite phase (see figure 10). Friedel pairs are 
related by the inversion through the origin and therefore exhibit negated indices (hkl and -h-k-l). When 
Friedel’s law is valid, the atomic scattering factor or atomic form factor ƒ0(θ) is a scalar function and 
depends only on the scattering angle θ and can be treated as a real number.  
 
Figure 10: The members of a Friedel pair exhibit equal amplitude and complementary phase when Friedel’s law is 
valid: |Fhkl| = |F-h-k-l|; αhkl = -α-h-k-l (adapted from (144)).  
 
 Some atoms can function as anomalous scatterers since the energy of the X-ray photons is close 
to a transition state of their inner shell electrons. In this case the incident X-radiation is elastically 
scattered but in addition partially absorbed to promote an electron from an inner shell to a higher shell. 
The excited electron is not able to sustain the higher energy level and falls back to a lower shell resulting 
in the emission of X-radiation (known as fluorescence). As consequence of the absorption of X-radiation, 
the atomic form factor is not longer a scalar function but becomes a vectorial quantity consisting of three 
components: the normal scattering term ƒ0(θ) which is dependent on the scattering angle, the dispersive 
term ƒ’(λ) and the absorption term ƒ’’(λ) that are not dependent on the scattering angle but on the 
wavelength. The full atomic form factor can be described as a complex number:  
 
)('')(')(),( 0  iffff         (2) 
θ = scattering angle  λ = wavelength     
f0 (θ) = normal scattering term  f ’’ (λ) = absorption term  
f ‘ (λ) = dispersive term   i = imaginary unit  
 
 The last two terms represent the anomalous scattering that occurs at the absorption edge of the 
atom (see figure 10), whereby the absorption term is 90° advanced in phase. The atoms usually present in 
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proteins possess a negligible ƒ’(λ) and ƒ’’(λ) due to the non-accessibility of their absorption edge by a X-
ray beam. The K-absorption edge of S for example is at λ = 5.0155 Å and therefore not accessible at a 
synchrotron X-ray source. In contrast, the K-absorption edge of Se is at λ = 0.9795 Å and for this reason 
accessible (see figure 11). The substitution of S-atoms by exogenously provided Se within a protein 
causes the presence of atoms that scatter anomalously since their atomic form factor contains an 
imaginary contribution iƒ’’ at the K-absorption edge (see figure 11). In this case Friedel’s law is not valid 
anymore and both the amplitude and phase relationship of the Friedel pairs are broken. This is illustrated 
in figure 12A and becomes more evident when one Friedel mate is reflected across the horizontal axis 
(see figure 12B): The reflections Fhkl and F-h-k-l exhibit different amplitudes and their phases are no longer 
complementary. The amplitude difference |+FNA| - |-FNA| is known as the Bijvoet difference.  
 Anomalous scattering can be utilized for phasing. The missing phase values can only be obtained 
through some prior knowledge of the structure. One possibility to achieve such knowledge is the 
localization of anomalously scattering Se atoms in the electron density map of the molecule by solving 
the so called Paterson map.  
 The Patterson function is a variation of the Fourier sum (1) that utilizes the structure factors 
(amplitudes and phases) to obtain a map of the electron density. The Patterson function uses solely the 
measurable intensities (amplitudes squared) and is therefore independent from the phase values: 
 
)(221),,( lwkvhui
hkl hkl
eF
V
wvu          (3) 
 
p (u,v,w) = peak value in the Patterson map at position u,v,w            e = Euler’s number               
V = volume of the unit cell      i = imaginary unit  
|Fhkl|= structure factor amplitude of the reflection hkl      
              
 The graph of this function is not a contour map of the electron density but rather a map that 
contains all interatomic vectors of the unit cell. The coordinates u,v,w locate a point in the Patterson map 
in the same way as coordinates x,y,z locate a point in the electron density map. Three peaks of three atoms 
in the electron density map give rise to 6 peaks in the Patterson map defined by moving the tails of the six 
possible interatomic vectors to the origin. The peaks of the Patterson map occur at the head of each 
vector. The origin and two of the six peaks in the map determine the location of the three real atoms in the 
unit cell. To solve the Patterson map, the origin and two additional peaks are chosen as a trial solution and 
the expected Patterson map for this specific arrangement of atoms is generated. The picked arrangement 
of the atoms is correct in case of congruence of the generated and the calculated Patterson map. For a 
small number of atoms (up to approximately 1000) it is possible to work out the original position of the 
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atoms in the unit cell by the described trial-and-error-method. Higher numbers of atoms (N real atoms in 
the electron density map give rise to N
2
-N peaks in the Patterson map) make it difficult to solve a 
structure by deconvolving the Patterson map due to its increasing complexity. Even at high resolution, 
electron density peaks are barely resolved and hence interdict the construction of a Patterson map with 
peaks resolved from each other.  
 The Patterson map of a reflection dataset derived from a Se-methionine substituted protein crystal 
exhibits prominent peaks that correspond to the Se atoms in the unit cell. The height of a peak in the 
Patterson map is proportional to the product of the heights of the two corresponding peaks in the electron 
density map. Selenium has 34 electrons and sulfur 16 electrons. According to that, a selenium peak in the 
Patterson map exhibits almost the fivefold intensity of a sulfur peak. The intensity discrepancy between 
selenium and other elements usually present in proteins is even higher causing their fading into the noise. 
This allows the calculation of a Patterson map that exclusively encompasses the Se atoms within a 
molecule and is for this reason of low complexity. The direct solution of this Patterson map gives rise to 
the substructure of Se atoms in the electron density of the molecule. As soon as the locations x,y and z of 
the anomalous scattering atoms is known the corresponding phases can be calculated.  
 At this stage of prior knowledge of the anomalous substructure, the green vectors in figure 11 are 
known in length and phase and can be used to calculate the phase of the vector FN and  with it the phase of 
the normal scattering molecules in the molecule. In case of a SAD experiment two solutions are possible 
for the phase αN as illustrated in figure 13. Figure 13A shows a so called Harker construction in which the 
intersection points of the two circles define the two possible phases αN (highlighted in orange). Figure 
13B represents an alternative way to illustrate the problem of the phase ambiguity. The two possible 
values of αN are symmetrically orientated about αA -90° and give rise to the same Bijvoet difference |+FNA| 
- |-FNA|. The unique determination of the protein phase is only possible when the phases αN and αA differ 
by 90°. In this case both solutions coincidence.  
 Different ways can be chosen to overcome the described phase ambiguity. One possibility is to 
carry out a MAD experiment (multiple anomalous dispersion). A SAD experiment is characterized by the 
measurement of anomalous scattering at one sole wavelength (usually at the absorption peak / K-edge (λ1) 
where the absorptive term FA’’ exhibits a local maximum; see figure 13A). In a MAD experiment 
anomalous scattering is recorded at least at one more wavelength (inflection point (λ2) where the 
dispersive term FA’ exhibits a local minimum, remote (λ3, λ4); see figure 14A). This procedure enables the 
determination of a further Bijvoet difference (see figure 14B) that allows complementation of the Harker 
construction shown in figure 12A by a third circle. This results in one coincident intersection point of all 
three circles, which defines a unique solution of αN. 
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 Another possibility is to collect data at just one single wavelength and to utilize density-
modification protocols to break the phase ambiguity. One method of density modification is solvent 
flattening that sets the electron density in the solvent regions to a typical value differing from the typical 
electron density of protein. This procedure smoothes the electron density map by eliminating random 
fluctuations in density and divides the map into two main subregions: those of relative high density 
caused by protein and those of relative low density caused by solvent. Flattening of the solvent region 
leads to higher accuracy of the corresponding phases and an enhanced contrast between protein and 
solvent. Solvent flattening requires phases, which are at least good enough to allow a boundary definition 
between the disordered solvent and the ordered protein. The solvent-protein boundary can be defined 
automatically by utilizing different algorithms.  
 
 
 
 
Figure 11: Variation in anomalous scattering of Se plotted against the energy of the X-ray beam (145). 
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Figure 12: (A) Breakdown of Friedel’s law in presence of an anomalous scatterer. The total structure factors FNA of 
the Friedel mates are shown in red and blue respectively. The contribution of normally scattering atoms is shown in 
black (FN) and that of anomalous scatterers in green (FA
0
, FA’, FA’’). The total structure factors FNA contain the 
normal scattering of all atoms FN (shown in black) and FA
0
 (shown in green), the dispersive component of the 
anomalously scattering atoms FA’ and the absorptive component of the anomalously scattering atoms FA’’. (B)  
Reflection of one Friedel mate across the horizontal axis illustrates the invalidity of Friedel’s law in the presence of 
an anomalous scatterer: |Fhkl| ≠ |F-h-k-l|; αhkl ≠ -α-h-k-l (adapted from (144)).  
 
Figure 13: SAD experiments result in a phase ambiguity which can be illustrated by a Harker construction (A) and 
an Argand diagram (B) showing the various contributions to the scattering factors. The total structure factors of the 
Friedel FNA mates are shown in red and blue respectively. The contribution of normally scattering atoms is shown in 
black (FN) and that of the anomalous scatterers in green (FA
0
, FA’, FA’’) (adapted from (146)).      
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Figure 14: MAD phasing. (A) Typical absorption curve of an anomalous scatterer (145). (B) Measurement of 
anomalous scattering at more than one wavelength allows the determination of further Bijvoet differences and 
breaks the phase ambiguity (adapted from (144)).  
 
2.2.12.3 Structure determination of the ssMDA5:PIV5 V protein core complex 
The structure of the ssMDA5:PIV5 V protein core complex was determined by SAD phasing. Diffraction 
data were collected at beamline ID23-2 of the European Synchrotron Radiation Facility (ESRF). 
Diffraction images of selenomethionine-substituted protein crystals were recorded at a wavelength of 
12.66127 keV (corresponds to the Se peak wavelength) with an oscillation range of ∆ ȹ = 1° per image. 
Processing of the collected diffraction data was carried out with XDS (147). The crystals contained one 
complex per asymmetric unit (37% solvent content) and belong to the space group P212121 with cell 
constants a = 51.07 Å, b = 52.49 Å, c = 120.79 Å, α = β = λ = 90°. The integrated and scaled reflection 
intensities/amplitude listed in the XDS output file allowed processing up to 2.3Å. The structure was 
determined by single wavelength anomalous dispersion using SHELXD (as part of AutoSHARP (148)) to 
locate selenium sites. Phase improvement was achieved by solvent-flattening using SOLOMON (as part 
of AutoSHARP (148)). The optimized experimental phases resulted in an electron density map whose 
quality was sufficient to operate initial automatic model building with Buccaneer (149). Besides of 5 
anomalous peaks in the anomalous difference map representing expected selenium atoms from the 
selenomethionine-substituted ssMDA5 protein, two additional anomalous peaks of zinc atoms belonging 
to the PIV 5 V protein could be identified. The initial model was refined in cyclic rounds of manual 
model building in COOT (150) and refinement using PHENIX (151). Refinement represents an iterative 
process in which the atomic model undergoes modification in usually five parameters for each atom: the 
three coordinates x,y and z which specify the position of each atom within the real space of the unit cell, 
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the B-factor (also known as temperature factor) which describes the attenuation of elastic x-ray scattering 
depending on the temperature and the occupancy Q. Occupancy Q represents the time that an atom spends 
at position x,y,z. Based on the modified model, structure factor amplitudes are calculated and the 
discrepancy between the calculated amplitudes |Fcalc| and the observed amplitudes |Fobs| is determined. The 
goal is to achieve a model that exhibits maximal agreement between |Fcalc| and |Fobs|. A refinement process 
can therefore be seen as a least squares method of the target function Σ (|Fobs| - k|Fcalc|)
2
, whereby k is a 
scale factor necessary to bring |Fcalc| and |Fobs| on the same scale. The final model comprising ssMDA5 
residues 546-808 and PIV5 V protein residues 168-219 showed good R-factors and stereochemistry. 
Atomic coordinates and structure factors were deposited in the Protein Data Bank with accession number 
4I1S. The crystallographic parameters of the structure are listed in tables 4 and 5 (see section 3.4). All 
figures were prepared with PyMol.  
 
2.2.13 Analytical size exclusion chromatography 
Purified mmMDA5 protein or mmRIG-I protein (purified as described in (55)) was diluted to a 
concentration of 15 µM. PIV5 V protein was added in molar excess (1:1.5 ratio) and the complex was 
incubated for 1h on ice. Analytical size exclusion experiments were performed on an Ettan LC system 
(Superdex200 5/150, GE Healthcare) using the complex formation buffer (see table 3) as running buffer.  
 
2.2.14 Differential scanning fluorimetry experiments 
Differential scanning fluorimetry experiments were carried out with 1µg/µl dilutions of MDA5 full length 
or MDA5 SF2 ATPase domain with or without PIV5 V-protein (purified stoichiometric complex) in 
50 mM Tris pH 7.5, 150 mM NaCl, 5 mM MgCl2, 10 µM ZnCl2, 5 mM DTT and a 5× dilution of SYPRO 
Orange dye (Invitrogen) as described
 
(152). The fluorescence signal as a function of temperature was 
recorded using a Real Time PCR machine (Bio-Rad). The temperature gradient was performed in the 
range of 10–70 °C with a ramp of 1 °C over the course of 60 min. 
 
2.2.15 Electrophoretic mobility shift assays (EMSAs) 
A 24bp RNA-palindrome purchased from Biomers (HPLC-grade) with following sequence was used:   
5`-GCGUCGUACGCUAGCGUACGACGC-3`. A fixed RNA concentration of 1 µM was incubated with 
the indicated amount of purified mmMDA5 in 50 mM Tris pH 8.0, 150 mM NaCl, 5 mM MgCl2, 10 µM 
ZnCl2 and 5 mM DTT reaction buffer. PIV5 V protein was added in 3-fold molar excess according to the 
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MDA5 concentration. Each incubation step was carried out for 40 min on ice. Samples were separated by 
native PAGE (5%) and analyzed by Gel-Red-staining (Biotium). 
 
2.2.16 Electron microscopy 
A solution containing 125 µg/ml of poly(I:C) (The Midland Certified Reagent Company) and 50 µg/ml 
mmMDA5 were incubated in absence or presence of 2.5 mM ATP and PIV5 V protein (in 1.2 molar 
excess to mmMDA5). The incubation was carried out for 40 min on ice at pH 7.4 in 50 mM NaH2PO4, 50 
mM Glycine, 14 mM Succinic acid, 10 mM MgCl2, 10 µM ZnCl2 and 5 mM DTT. The mixtures were 
applied to pre-coated Quantifoil holey carbon-supported grids and negatively stained using 2% uranyl 
acetate (performed by Charlotte Ungewickell, laboratory of Prof. Dr. Roland Beckmann, Gene Center, 
Munich). Grids were examined with the help of Günter Pfeifer (Max Planck Institute of Biochemistry, 
Martinsried) on a CM20 FEG Philips at 160 kV and images were recorded with a 4k x 4k CCD camera 
(Tietz).  
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3. Results  
 
3.1 Recombinantly expressed full length MDA5 is a functional protein 
At the beginning of the work presented in this thesis, MDA5 was poorly characterized in terms of its 
atomic structure. With the exception of the isolated MDA5 RD, no structural information concerning 
further domains or their interplay in viral RNA ligand recognition existed. Crystallization of MDA5 and 
other RLRs was a major goal as the key towards understanding of their detailed function lies in the 
molecular structure of the receptors. To achieve the task of MDA5 crystallization in complex with the 
inhibitory paramyxoviral V protein and to gain maximal structural insight into the receptor, different full 
length MDA5 constructs of different species were cloned and tested for soluble expression in E.coli. 
Mouse (mm, mus musculus) and chicken (gg, gallus gallus) MDA5 recombinantly expressed as His-
tagged versions were found to be soluble and to be produced in high yields required for crystallization 
(see figure 15). Both full length proteins could be purified to sufficient homogeneity (see figure 16A) and 
showed no sign of aggregation in size exclusion chromatography (see figure 17).  Activity assays revealed 
that mmMDA5 as well as ggMDA5 purified from E.coli were able to hydrolyse ATP in the presence of 
the synthetic dsRNA ligand poly(I:C) (see section 1.2.1), indicating that both proteins are natively folded 
and functional (see figure 16B).  
 The two purified MDA5 orthologs were tested for their ability to bind purified PIV5 V protein. 
Both, mmMDA5 as well as ggMDA5, were found to form a stoichiometric complex with the V protein 
that was stable in size exclusion chromatography (see figure 17). Further investigation using static light 
scattering (SLS) measurements (see section 2.2.7) revealed that MDA5 is a monomeric protein in solution 
and binds the PIV5 V protein with a stoichiometry of 1:1 (see figure 18). Complexes comprising full 
length MDA5 and full length PIV5 V protein isolated by size exclusion chromatography were of 
sufficient quality (see figure 17B) for crystallization trials. However, none of the purified full length 
complexes tested under various screening conditions was observed to form crystals.  
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Figure 15: Testexpression of N-terminally His-tagged full length MDA5 of different orthologs (mm = mus 
musculus, bt = bos taurus, gg = gallus gallus, ss = sus scrofa) analyzed by SDS-PAGE and Coomassie staining. 
Recombinant expression was performed in Escherichia coli Rosetta (DE3) for 18h at 20°C with indicated ITPG 
concentrations. PF = pellet fraction containing unsoluble protein. SF = soluble protein fraction. BF = bead fraction 
(soluble proteins eluted from Ni-NTA agarose beads). Conditions and constructs that gave rise to best expression 
yields of soluble protein are highlighted in bold and indicated by red stars.  
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free γ-32P
γ- 32P-ATP
A B
 
Figure 16: (A) Purified full length mmMDA5 and ggMDA5 analyzed by SDS-PAGE and Coomassie staining. (B) 
ATPase assay showing the ATPase activity of the purified full length proteins used in crystallization trials and 
biochemical assays. Poly(I:C)-stimulated mmMDA5 or ggMDA5 (0 µM, 1µM, 2.5 µM, 5 µM, 10 µM and 15 µM) 
was incubated with γ-32P-ATP. Liberated and TLC-separated γ-32P was visualized with a phosphorimager. 
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Figure 17: (A) Analytical size exclusion chromatogram of full length mmMDA5 in absence (blue elution profile) 
and presence of purified PIV 5 V protein (orange elution profile). V protein biding is reflected in an increase of the 
hydrodynamic radius causing a shift of the protein peak to smaller elution volume. The solid line in orange marks 
fractions analyzed by SDS-PAGE and Coomassie staining revealing stochiometric coelution of full length 
mmMDA5 and PIV5 V protein. (B) SDS-PAGE analysis (Coomassie staining) of finally purified and concentrated            
full length MDA5:PIV5 V protein complexes used in crystallization trials.  
 
 
 
mmMDA5
mmMDA5 +
PIV5 V
Measured Mw: 118.08 kDa
Theoretical Mw of a MDA5 monomer: 118.42 kDa
Measured Mw: 142.48 kDa
Theoretical Mw of 1:1 complex : 142.69 kDa
 
Figure 18: Multiangle static light scattering experiments in combination with size exclusion chromatography were 
performed to determine the absolute molar mass of full length mmMDA5 in isolation (left panel) and in complex 
with PIV5 V protein (right panel) in solution. The measured mean values of the molecular weight (Mw) of 
isocratically eluted mmMDA5 and mmMDA5:PIV5 V protein complex testify a monomeric state of full length 
MDA5 and a 1:1 stoichiometry of the MDA5:PIV5 V protein complex in solution (theoretical Mw of the PIV5 V 
protein: 24.27 kDa).  
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3.2 Optimization of protein constructs for crystallization  
Ab initio protein models calculated from SAXS data revealed that monomeric full length MDA5 adopts 
an elongated, non-globular conformation in solution (see figure 19). The shape of the MDA5 full length 
molecule is characterized by several lobes and defined by multiple centers of mass (see also section 2.2.8 
and figure 33 of section 3.6). The extended, multipart shape of the protein suggests that the single 
domains (CARDs, SF2 ATPase domain, RD) of free MDA5 might be connected by flexible linkers 
allowing them to change their relative position to each other within the MDA5 molecule. Suchlike linkage 
would explain why full length MDA5 is prone to degradation in testexpression as well as in purification 
(see figures of section 3.1) indicating that non-compact, flexible parts are exposed and accessible for 
proteases. Binding of the PIV5 V protein to MDA5 was not found to cause a compaction of the MDA5 
full length molecule. Ab initio models calculated from SAXS data derived from purified MDA5:PIV 5 V 
protein complexes showed that V protein binding rather enhances elongation of the MDA5 molecule that 
appears to be stretched by the V protein (see figure 19 and also figure 33 of section 3.6).  
 
mmMDA5 mmMDA5 + PIV5 V protein
 
 
Figure 19: Ab intio protein models of mmMDA5 alone (shown in blue) and in complex with PIV5 V protein (shown 
in orange) obtained by SAXS analysis. The Apaf 1 CARD (shown in cyan, PDB code: 2P1H), the Hef SF2 ATPase 
domain (shown in mauve, PDB code: 1WP9) and the RD of hsMDA5 (shown in black, PDB code: 3GA3) were 
modeled into the electron density shape of full length mmMDA5. 
 
 
The assumed intrinsic flexibility of the MDA5 molecule was considered to prevent or hinder 
crystallization of the full length MDA5:PIV5 V protein complex. To address this problem, further MDA5 
constructs combining different domains of the protein were purified in complex with PIV5 V protein and 
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screened for crystallization. Figure 20 shows representative complexes of PIV5 V protein and RD- or 
CARD-less MDA5 constructs after size exclusion chromatography. None of the truncated complexes 
tested under various screening conditions was observed to form crystals.  
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Figure 20: SDS-PAGE analysis (Coomassie staining) of truncated MDA5:PIV5 V protein complexes purified by 
size exclusion chromatography and used in crystallization trials. The C-terminally His-tagged MDA5 constructs are 
illustrated in schemes. Hs = homo sapiens, mm = mus musculus.  
 
 
In a next step, as RD- and CARD-less MDA5 constructs did not succeed in crystallization, various 
constructs of the MDA5 SF2 ATPase domain with different N- and C-termini were generated and tested 
for soluble expression in E.coli. Figure 21 shows the testexpression results of C-terminally His-tagged 
SF2 ATPase versions of three different MDA5 orthologs. Constructs with a C-terminus solely comprising 
the C-terminal RecA-like fold of the SF2 ATPase domain were found to be either unexpressed or low 
expressed. In contrast, constructs whose C-terminus contain the C-terminal RecA-like fold and two 
downstream, well conserved α-helices (according to amino acid sequence alignments and secondary 
structure predictions) gave rise to high expression levels (see figure 21). These two additional α-helices 
that characterize the SF2 ATPase domain of all RLR family members were later found to form a 
functionally important, V-shaped linker within the RNA clamp structure of RIG-I and MDA5 (see 
sections 1.3.1 and 1.3.2).          
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Figure 21: Testexpression of C-terminally His-tagged MDA5 SF2 ATPase domain constructs (N-and C-termini as 
indicated) of different orthologs (hs = homo sapiens, mm = mus musculus, gg = gallus gallus) analyzed by SDS-
PAGE and Coomassie staining. Recombinant expression was performed in Escherichia coli Rosetta (DE3) for 18h 
at 20°C with final ITPG concentration of 0.1 mM IPTG. PF = pellet fraction containing unsoluble protein. SF = 
soluble protein fraction. BF = bead fraction (soluble proteins eluted from Ni-NTA agarose beads). Constructs that 
gave rise to expression yields sufficient for crystallization are highlighted in bold.  
 
 
SF2 ATPase domain constructs proven to be expressed in sufficient yields (see figure 21) were purified in 
complex with PIV5 V protein and screened for crystallization. None of the SF2 ATPase:PIV5 V protein 
complexes tested under various screening conditions was observed to form crystals.  
 Amino acid sequence alignments of RLR family members revealed a loop region within the α-
helical insertion of the MDA5 SF2 ATPase domain, that is missing in case of  LGP2 as well as RIG-I and 
predicted to be unstructured (see figure 22). To optimize MDA5 SF2 ATPase constructs for 
crystallization, this likely flexible loop was replaced by a short SGSGS-linker. A similar strategy was 
applied in case of the PIV5 V protein. A large loop region of 25 amino acids found to be unstructured in 
this V protein (104) was replaced by a GSGSGSGSGS-linker to increase the probability of crystallization. 
Figure 23 shows engineered MDA5 proteins of six MDA5 orthologs after purification and complex 
formation with modified PIV5 V protein. None of the optimized SF2 ATPase:PIV5 protein complexes 
tested under various screening conditions was observed to form crystals.  
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hsMDA5           613
mamMDA5           613
ssMDA5           612
btMDA5           611
cfMDA5           614
ggMDA5           605
hsRIG-I          554
hsLGP2          293
α α
Figure 22: Amino acid sequence alignment of the SF2 ATPase loop region of selected RLR family members with 
annotated secondary structure elements. Residue conservation is color-coded according to percentage identity. Hs = 
homo sapiens, mam = macaca mulatta, ss = sus scrofa, bt = bos taurus, cf = canis familaris, gg = gallus gallus.  
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Figure 23: SDS-PAGE analysis (Coomassie staining) of finally purified and concentrated MDA5 SF2 ATPase:PIV5 
V protein complexes with flexible loops replaced by GS-linkers as indicated and used in crystallization trials. Hs = 
homo sapiens, mm = mus musculus, gg = gallus gallus, tg = taeniopygia guttata, bt = bos taurus, ss = sus scrofa.  
 
 
3.3 Crystallization of the ssMDA5:PIV5 V protein core complexes 
One major issue regarding crystallization of the MDA5:V protein complex is its strong tendency to form 
heavy precipitate in crystallization screens. Even at very low protein concentrations (in the range of 0.5-
1.0 mg/ml) each and all of the described protein constructs immediately precipitated in crystallization 
experiments. Crystals are formed when proteins “precipitate” very slowly from a supersaturated solution 
in an ordered manner. The misbehavior of the MDA5:V protein complex made it impossible to define a 
reasonable protein concentration range that would allow such a crystallization process and to identify 
useful conditions for crystal generation. Alteration of major parameters known to influence crystallization 
and crystal growth (e.g. temperature, nature and concentration of the precipitant, organic and inorganic 
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additives) did not resolve the problem of strong precipitation. Reductively methylated MDA5 proteins 
purified in complex with PIV5 V protein and complexes purified in high salt buffers (the MDA5:PIV5 V 
protein complex was found to be stable at 1M NaCl in size exclusion chromatography) did not increase 
solubility either.  
 Another strategy that was applied to prevent immediate precipitation of the MDA5:V protein 
complex in screening experiments was its co-crystallization with Fab fragments. It was further assumed 
that Fab fragments might stabilize the MDA5:PIV5 V protein complex and allow crystallization by 
providing crystal contacts. The Fab fragments were derived from monoclonal antibodies recognizing 
either mmMDA5 or PIV5 V protein (see section 2.2.10). Figure 24 shows a pulldown assay that was 
performed with supernatants of different hybridoma cell lines to identify monoclonal antibodies that were 
able to bind natively folded full length mmMDA5 purified from E.coli. Further selection rounds based on 
similar pulldown approaches were used to identify PIV 5 V protein binders, binders that specifically 
recognize the MDA5 SF2 ATPase domain and binders that do not interfere with complex formation of the 
two proteins.  
 
mmMDA5 
heavy chain 
light chain  
 
 
Figure 24: Pulldown assay applied to identify monoclonal IgG antibodies that are able to recognize natively folded 
full length mmMDA5 purified from E.coli and analyzed by SDS-PAGE and Coomassie staining. The assay was 
performed with supernatants of indicated hybridoma cell clones and protein G beads. NC = negative control 
performed with full length mmMDA5 and protein G beads. Positive clones are highlighted in bold.  
 
 
 IgG antibodies of four positive clones (namely the mmMDA5 recognizing clones GGS/M 4A9, 
GGS/M 12G5 and the PIV5 V protein recognizing clones GGSV 12C10, GGSV 16B5) were subjected to 
papain digest. The produced and purified Fab fragments were tested for their ability to form stable, 
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stoichiometric triple complexes with preformed MDA5:V protein complexes in size exclusion 
chromatography (see figure 25). Three high affinity binders (namely GGS/M 4A9, GGSV 12C10 and 
GGSV 16B5) could be identified and were used for co-crystallization trials with different MDA5:PIV5 V 
protein constructs. Although binding of Fab fragments significantly increased the solubility of the 
MDA5:PIV5 V protein complex in crystallization experiments, none of the Fab triple complexes tested 
under various screening conditions was observed to form crystals.  
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Figure 25: Analytical size exclusion chromatography experiments performed to select Fab fragments of sufficient 
affinity to form stable triple complexes with preformed MDA5:PIV5 V protein complexes. Positively tested Fab 
fragments are highlighted in bold. Blue elution profiles are based on the absorption at 280 nm, red elution profiles 
are based on the absorption at 260 nm. MmMDA5 SF2 = mus musculus MDA5 SF2 ATPase domain. Solid lines 
mark fractions analyzed by SDS-PAGE and Coomassie staining.   
 
 
 The goal of MDA5:PIV5 V protein crystallization was finally achieved by an in-drop proteolysis 
approach. The loop-truncated complexes of MDA5 SF2 ATPase domains and PIV5 V protein shown in 
figure 23 were mixed with different proteases (subtilisin, chymotrypsin or trypsin) before being used in 
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crystallization experiments. Among six complexes tested, the truncated ssMDA5 SF2 ATPase domain in 
complex with truncated PIV5 V protein (see figure 26A) was found to form crystals in the presence of 
trace amounts of trypsin (see figure 26B and section 2.2.11). The plate-shaped crystals obtained in 
commercial crystallization screens were optimized and converted to a more three-dimensional shape by 
hanging-drop vapour diffusion and streak seeding (see figures 26C and 26D). Native as well as 
selenomethionine-substituted protein crystals diffracted to a resolution of 2.3 Å (see figure 26E).  
 
ssMDA5 P303-R887
E641-K665 
replaced by SGSGS
ssMDA5 K463-R887
E641-K665 
replaced by SGSGS
PIV5 V protein
A55-P79 replaced by 5xGS
A B C
D
E
 
 
Figure 26: (A) Purified MDA5:PIV5 V protein complex that crystallized in the presence of trypsin. The co-purified 
impurity could be identified as N-terminally truncated fragment of the ssMDA5 SF2 ATPase domain. (B) Initial 
plate-shaped crystals that appeared in a commercial crystallization screen (condition: 100 mM Hepes pH 7.5, 20% 
(w/v) PEG 1500). (C) Refined crystals in the final condition (100 mM Hepes pH 7.5, 18% (w/v) PEG 1500).         
(D) Crystals optimized by streak seeding in the final condition. (E) Diffraction image of selenomethionine-
substituted protein crystals recorded at beamline ID23-2 of the European Synchrotron Radiation Facility (ESRF). 
 
 
3.4 The paramyxoviral V protein disrupts the fold of the MDA5 SF2 ATPase domain 
The presence of a protease in the crystallization condition raised the question which actual portion of the 
purified ssMDA5 SF2 ATPase:PIV5 V protein complex the crystals contain. The selenomethionine 
derivative of the ssMDA5 SF2 ATPase in complex with unlabeled PIV5 V protein crystallized in the 
same condition as the native complex and allowed structure determination by experimental phasing using 
SAD data (see section 2.2.12.3). The quality of the calculated electron density map was sufficient to place 
a first model (see figure 27A) using the autobuilding program Buccaneer (149). According to this initial 
model the crystals apparently contained the α-helical insertion as well as the C-terminal RecA-like fold of 
the ssMDA5 SF2 ATPase domain, but no portion of the PIV5 V protein. 
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Figure 27: (A) Initial unrefined structure model obtained with Buccaneer (149). The C-terminal RecA-like fold of 
the ssMDA5 SF2 ATPase domain with annotated β-strands is shown in dark blue and the α-helical insertion domain 
in light blue. (B) Superposition of the ssMDA5 model shown in (A) (in dark blue) with equivalent parts of the 
mmRIG-I SF2 ATPase domain (PDB code: 3TBK) (in yellow). The opposite orientation of β-strand 1 within the C-
terminal RecA-like fold is indicated by a red arrow.  
 
 Superposition of the model obtained with Buccaneer and equivalent parts of the RIG-I SF2 
ATPase domain confirmed their high similarity in fold and arrangement, but demonstrated opposite 
orientation of the β-strand 1 within the C-terminal RecA-like fold (see figure 27B). Refinement of the 
initial model by manual model building revealed further that residues of ssMDA5 belonging to the β-
strands 1 and 6 within the C-terminal RecA-like fold did not fit in the assigned part of the electron density 
map. This paradox and the knowledge that the PIV5 V protein contains a zinc binding motif suggested the 
calculation of an anomalous difference Patterson map that uses the anomalous difference at the peak 
wavelength to locate anomalous scatterers. Besides of 5 anomalous peaks representing expected selenium 
atoms from the selenomethionine-substituted ssMDA5 protein, two additional anomalous peaks of zinc 
atoms could be identified. This information revealed the actual identity of the β-strands 1 and 6 assumed 
to be part of the ssMDA5 protein. These two β-strands do not belong to the C-terminal RecA-like fold of 
MDA5, but rather represent the conserved zinc binding motif of the V protein CTD (see section 1.5.1). 
Thus, the structure represents the evolutionary conserved, necessary and sufficient core of the MDA5:V 
protein complex (131, 134-136) (see also section 1.5.3). Figure 28 shows the final refined structure of the 
ssMDA5:PIV5 V protein core complex with the assigned zinc ions of the V protein CTD. 
Crystallographic data and refinement statistics are summarized in tables 4 and 5.  
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Figure 28: Structure of the ssMDA5:PIV5 V core complex with annotated β-strands. The ssMDA5 α-helical 
insertion is shown in light blue, the ssMDA5 C-terminal RecA-like fold in dark blue and the zinc binding motif of 
the PIV5 V C-terminal domain (CTD) in orange. Zinc ions are highlighted in grey.  
 
 
 
 
Table 4: Summary of crystallographic data (*highest resolution shell is shown in parenthesis). 
Data collection  
Beamline ESRF ID23-1 
Wavelength (Å) 0.9792 
Spacegroup P212121 
Cell dimensions  
     a, b, c  (Å) 51.07, 52.49, 120.79 
     α =β=γ (°) 90 
Resolution (Å)* 50-2.3 (2.35-2.29) 
Rmerge (%)* 13.7 (83.8) 
I/σI* 13.64 (2.58) 
Completeness (%)* 99.2 (90.4) 
Redundancy* 7.17 (6.77) 
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Table 5: Summary of refinement statistics.  
Refinement  
Resolution 48.14-2.29 
No. of Reflections 27853 
Rwork/Rfree (%) 17.92/22.96 
No. of atoms  
     Protein 2377 
     Zn
2+
 2 
     Water 110 
B-factors  
     Protein 41.96 
     Zn
2+
 51.12 
     Water 39.74 
R.m.s deviations  
     Bond length (Å) 0.009 
     Bond angles (°) 1.173 
Ramachandran (residues / %)  
     favoured 269 /95.7 
     allowed 12 / 4.3 
     outlier 0 / 0 
PDB code 4I1S 
 
 
 Along with the identification of the viral zinc binding motif it becomes evident how the PIV5 V 
protein binds to its target MDA5. The typical C-terminal RecA-like fold of ATPases is characterized by a 
central β-sheet with parallel strands in the order β3-β4-β2-β5-β1-β6 (see figure 27) (24). In the 
determined structure, the CTD of the V protein forms a continuous β-sheet with the C-terminal RecA-like 
fold of MDA5 in the order β3MDA5-β4MDA5-β2MDA5-β5MDA5-β1VCTD-β2VCTD (see figure 28). This 
arrangement implies that the V protein integrates itself into the structure of MDA5. Apparently, it melts 
the central β-sheet of the RecA-like fold and replaces its canonical β-strands 1 and 6 by the two β-strands 
of the zinc binding motif.  In this way, the CTD of the V protein creates a mimic of the C-terminal RecA-
like fold that hampered its identification in the structure (see figure 27).  
 Superposition of the MDA5:V protein core complex and the complete RIG-I SF2 ATPase domain 
(see figure 29) implies that the insertion of the V protein is for steric reasons incompatible with the 
canonical arrangement and tertiary structure of the MDA5 SF2 ATPase domain. In absence of the V 
protein the two conserved helices of the V-shaped linker mediate contacts between the N- and C-terminal 
RecA-like fold (see also section 1.3.1) (26, 29, 30, 60). The displacement of the MDA5 β-strand 1 (which 
forms a connection between the N-terminal RecA like fold and the α-helical insertion (30)) and the 
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MDA5 β-strand 6 (which lies directly upstream of the V-shaped linker (30)) by the CTD of the V protein 
is assumed to interfere with these interactions. The presence of the V protein is believed to severely 
disturb the normal architecture of the MDA5 SF2 ATPase domain and assumed to cause a disruption or 
partial unfolding of the ATPase domain. Such a scenario might explain why the MDA5:V protein 
complex did not crystallize (see sections 3.1-3.3) or solely crystallized in the presence of a protease that 
allowed cleavage of possible flexible portions. These portions include the N-terminal RecA-like fold, the 
β-strands 1 and 6 of the C-terminal RecA-like fold and the V-shaped linker of the ssMDA5 protein as 
well as the N-terminal domain (NTD) of the PIV5 V protein. All of these were present in the protein 
constructs used for crystallization but not in the determined crystal structure.  
 
 
  
Insertion
Insertion
CRecA
CRecA
NRecA
NRecA
VCTD
VCTD
90°
V-shaped 
linker
V-shaped 
linker  
Figure 29: Superposition of the ssMDA5:PIV5 V core complex and the mmRIG-I SF2 ATPase domain (PDB code: 
3TBK) with annotated domains and structural elements. The mmRIG-I SF2 ATPase domain is shown in yellow, 
ssMDA5 parts in dark blue and the PIV5 V C-terminal domain (CTD) in orange. Zinc ions are highlighted in grey. 
The N-terminal RecA-like fold, the β-strands 1 and 6 of the C-terminal RecA-like fold and the V-shaped linker of 
the ssMDA5 protein as well as the N-terminal domain (NTD) of the PIV5 V protein are not present in the structure, 
presumably because of proteolytic cleavage.  
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3.5 Differences in residue conservation enable RIG-I to evade V protein recognition 
Figure 30A shows the interactions within the interface between β-strand 5 of the ssMDA5 C-terminal 
RecA-like fold and β-strand 1 of the PIV5 V protein CTD in detail. The interface is dominated by 
hydrophobic interactions, but E 174
PIV5
 forms sequence-specific hydrogen bonds and ion pair interactions 
with R803
ssMDA5
. E174
PIV5
 as well as R803
ssMDA5 
are highly conserved among V proteins and MDA5 
proteins, respectively (see figure 30B). Whereas LGP2 protein shares the conservation of R803
ssMDA
, 
RIG-I proteins possess a conserved leucine residue at this position (see figure 30 B). These findings 
explain why paramyxoviral V proteins are able to bind MDA5 as well as LGP2 across species barriers, 
but not RIG-I (see figures 23 and 30C). The leucine residue allows RIG-I proteins to evade recognition by 
paramyxoviral V proteins as it provides no anchoring point for salt bridge formation with the viral 
glutamate residue.  
 
 
PIV5 V β1
MDA5 β5
W179
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R803
E174
R172
PIV5 V
LGP2/RIG-I
LGP2 SF2 ATPase domain RIG-I SF2 ATPase domain
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Figure 30: (A) Close-up views of the intermolecular ssMDA5:PIV5 V interactions. Salt bridge formation is 
indicated by dashed lines. SsMDA5 parts are shown in blue an PIV5 V protein parts in orange. (B) Structure-based 
alignments of the interface sequences of selected RIG-I like receptors (upper panel) and paramyxoviral V proteins 
(lower panel) with highlighted conserved motifs and residues (according to percentage identity). Stars indicate 
residues involved in interface interactions; filled stars indicate residues mutated in this study. (C) Stoichiometric 
coelution of the ssLGP2 SF2 ATPase domain (left panel) and separate elution of the mmRIG-I SF2 ATPase domain 
(right panel) and PIV5 V protein in size exclusion chromatography analysed by SDS-PAGE and Commassie 
staining.  
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 The ssMDA5:PIV5 V protein structure and sequence alignments revealed a second important 
difference in residue conservation among RLR family members that has critical impact on V protein 
binding. G805
ssMDA5
, that is highly conserved among MDA5 and LGP2, stacks against W179
PIV5
 and 
allows it to insert into a hydrophobic pocket (see figure 30A). Instead of the glycine residue, RIG-I 
proteins have a conserved glutamate residue at this position, which sterically hinders the insertion of the 
conserved viral tryptophan residue (see figure 30B).      
 
  To confirm the interface observed in the ssMDA5:PIV5 V protein crystal structure and to 
approve importance of the found interactions, mutants of full length mmMDA5 as well as full length 
PIV5 V protein were generated and tested for their ability to form stable complexes in size exclusion 
chromatography (see figure 31A). Whereas wild type mmMDA5 shows stoichiometric coelution with 
wild type PIV5 V protein (see also section 3.1), a single amino acid exchange of R806
mmMDA5
 (equivalent 
to R803
ssMDA5
) with leucine (as found in RIG-I) completely abolishes the interaction in size exclusion 
chromatography. Likewise, mutation of E174
PIV5 
to alanine strongly reduces the in vitro binding. These 
studies verify that the structurally identified salt bridge is crucial for V protein binding to MDA5 and 
indicate evolutionary conservation of the binding mode.  
 To test if the structure-derived model of MDA5 recognition by paramyxoviral V proteins is 
sufficient to allow implementation of V protein binding in RIG-I proteins, full length mmRIG-I was 
mutated and tested for V protein interaction (see figure 31B). Wild type mmRIG-I shows no binding of 
PIV5 V protein in size exclusion chromatography. A single amino acid exchange of L715
mmRIG-I
 with 
MDA5’s arginine was found to be insufficient to induce V protein binding. The introduction of a second 
mutation replacing E716
mmRIG-I by MDA5’s glycine assumed to release the steric clash with W179PIV5 led 
to interaction with PIV5 V protein that was partly stable in gel filtration. Thus, the engineered RIG-I 
double mutant validates the structural findings by gain of function.  
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Figure 31: Analytical size-exclusion chromatograms of mmMDA5, mmRIG-I, PIV5 V protein and mutants as 
indicated. Starting concentration is 15 µM for MDA5/RIG-I and 22.5 µM for PIV5 V protein. Elution profiles for 
MDA5 are in blue, for RIG-I in red and for MDA5- or RIG-I-V-mixtures in orange. Solid lines mark fractions 
analyzed by SDS-PAGE and Commassie staining. The coelution of proteins indicates their interaction. (A) 
Mutations affecting the salt bridge between R806 of mmMDA5 and E174 of PIV5 V protein abolish or significantly 
impair their interaction. (B) Detectable binding of PIV5 V protein to mmRIG-I in size exclusion chromatography 
requires two mutations within the RIG-I SF2 ATPase domain: L715R is thought to enable ion pairing with E174 of 
PIV5 V protein and E717G is thought to reduce steric hindrance within the RIG-I:V protein interface.  
 
 
3.6 The PIV5 V protein has to unfold itself to disrupt the fold of MDA5 
In the crystal structure of PIV5 V protein bound to DDB1 (104) (the substrate recruiting adaptor protein 
of the ubiquitin ligase Cul4A, see also sections 1.5.1 and 4.4) the two β-strands of the C-terminal zinc 
binding motif form a continuous β-sheet with the NTD (see figure 32A). This central β-sheet is 
sandwiched by one α-helix and long loops of the NTD. Provided that the isolated unbound form of the 
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PIV5 V protein adopts a similar structure, the V protein must undergo a large conformational change to 
release the CTD for binding to MDA5. These observations suggest that the PIV5 NTD might shield the 
CTD in absence of MDA5, but exposes the CTD in presence of MDA5 (see figure 32). Whereas the two 
β-strands of the exposed CTD incorporate into the C-terminal RecA-like fold of MDA5 in order to disrupt 
its SF2 ATPase domain, the free NTD might adopt the unfolded conformation found in P protein (106).  
  Figure 32B compares the intermolecular ssMDA5:PIV5 V
CTD 
and the intramolecular PIV5 
V
NTD
:V
CTD
 interactions observed for the PIV5 V protein in complex with DDB1 (104). Both interfaces 
share high similarity. The NTD of the PIV5 V protein even mimics the salt bridge observed in the 
MDA5:PIV5 interface via R143
PIV5
 that binds to E174
PIV5 
(see figure 32B). The NTD also provides a 
hydrophobic pocket for W179
PIV5
. This implies, however, that all these interactions between the NTD and 
CTD have to be relieved to allow MDA5 binding.  
 In agreement with the assumed unfolding processes of the MDA5 SF2 ATPase domain and the 
PIV5 V protein upon complex formation are results of small angle X-ray scattering (SAXS) experiments 
performed with mmMDA5 and mmMDA5:PIV5 V protein complexes (see figure 33). SAXS measures 
the distribution of intermolecular distances in proteins in solution. The pair distance distribution function 
(see also section 2.2.8) can be understood as a two-dimensional Patterson function that describes the 
paired set of all distances between all electrons within a protein. The position where the pair distance 
distribution returns to zero represents the maximum length in the particle (Dmax). The pair distribution 
functions and ab inito models demonstrated a distinct increase in Dmax of the mmMDA5 full length 
molecule as well as the SF2 ATPase domain in presence of the PIV5 V protein (see figure 33A and B, see 
also figure 19 of section 3.2). Without knowledge of structural details, it was assumed that paramyxoviral 
V proteins recognize a conserved surface patch of MDA5 and bind on top of its SF2 ATPase domain 
resulting in an increased Dmax. However, the determined structure of the MDA5:V protein core complex 
revealed that V proteins rather recognize a conserved motif buried in the SF2 ATPase domain. The 
observed expansion of the MDA5 molecule and the increased Dmax-values apparently reflect wedging of 
the C-terminal zinc binding motif into the β-sheet of MDA5’s C-terminal RecA-like fold and loosening of 
interactions within the SF2 ATPase domain (see section 3.4 and figure 33C).  
 Differential scanning fluorimetry experiments examining the thermostability of purified proteins 
revealed a significant increase by approximately 10°C of the transition midpoint of different MDA5 
protein constructs in presence of the PIV5 V protein (see figure 34). These data imply that the conserved 
core of the MDA5:V protein complex is highly stable. For the PIV5 V protein itself it was not possible to 
determine a reasonable transition midpoint of protein unfolding indicating structural instability of the 
PIV5 V protein in isolation. Formation of a highly stable core within the MDA5:V protein complex might 
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favor V protein binding to MDA5 and this stabilization effect might outbalance negative effects of 
potentially unfolding processes (see section 3.4).  
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Figure 32: (A) Crystal structure of the PIV5 V protein in complex with DDB1 (not shown here; PDB code: 2HYE). 
The N-terminal domain (NTD, shown in light blue) has to release the C-terminal zinc binding motif (CTD, shown in 
orange) to allow binding to MDA5.  (B) Close-up views of the intramolecular PIV5 V
NTD
:V
CTD 
(left panel)
 
and the 
intermolecular ssMDA5:PIV5 V
CTD 
interactions (right panel). Salt bridges are indicated by dashed lines. Parts of 
ssMDA5 and of the PIV5 NTD are shown in light blue. Parts of the PIV5 CTD are shown in orange. 
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Figure 33: (A) Pair-distribution functions obtained by GNOM (138) of full length mmMDA5 (lower panel) or 
mmMDA5 SF2 ATPase domain (upper panel) in absence (shown in blue) and presence of PIV5 V protein (shown in 
orange) with indicated maximum particle sizes (Dmax). (B) Final averaged ab initio models of the mmMDA5
 
SF2 
ATPase domain in isolation (shown in blue) and in complex with PIV5 V protein (shown in orange). (C) Possible 
scenarios that cause an increase in Dmax in SAXS. The last panel represents the assumed model.  
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Figure 34: Thermostability of MDA5 in isolation and in complex with PIV5 V protein. Binding of the V protein 
increases the thermostability of different MDA5 constructs and species (mouse (mm) MDA5 full length, human (hs) 
MDA5 CARDless, human (hs) MDA5 SF2 ATPase domain) by approximately 10°C. The differential scanning 
fluorimetry experiments are either illustrated as melting curves (A) or as bars (B). The bars represent mean melting 
temperatures and the error bars indicate the standard deviation from five independent measurements. 
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3.7 V protein binding has dual impact on the function of MDA5 
The insertion of the paramyxoviral C-terminal zinc binding motif displaces not only β-strand 1 and β-
starnd 6 of MDA5’s C-terminal RecA-like fold, but also motif VI. This conserved motif, which MDA5 
shares with all other members of the SF2 helicase family and is known to be essential for ATP binding 
and hydrolysis (24),  is normally located between β-strand 5 and β-strand 6 (see figure 35) at the interface 
between the N- and C-terminal RecA-like folds. The crystal structure of the RIG-I SF2 ATPase domain in 
complex with an ATP transition state analog suggests that arginine residues of motif VI could bind the γ-
phosphate of ATP (60). It was further proposed that one of the arginine residues within motif VI 
functions as an “arginine finger” that could stabilize the water-Mg2+-β/γ phosphate intermediate in the 
course of the ATP hydrolysis reaction (24). The displacement of motif VI and general interference with 
the normal and functional architecture of  the SF2 ATPase domain (see section 3.4) explain why 
paramyxoviral V proteins are able to abrogate the ATP hydrolysis activity of MDA5 (see section 1.5.3 
and figure 8). 
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Figure 35: (A) Comparison of the functional C-terminal RecA-like fold of mmRIG-I
 
(PDB code: 3TBK)  and (B) 
the C-terminal RecA-like fold of ssMDA5 hijacked by the C-terminal domain (CTD) of PIV5 V protein with 
annotated β-strands and conserved motifs.  
 
 
 To investigate if V protein binding also interferes with the RNA binding activity of MDA5, 
electrophoretic mobility shift assays (EMSAs) with full length mmMDA5 were performed in absence and 
presence of PIV5 V protein (see figure 36A). These experiments revealed that the PIV5 V protein induces 
substantial changes of the MDA5 RNA-binding mode. In absence of V protein, mmMDA5 shifted a 24bp 
RNA predominantly to a single species with a slight amount of a faster migrating species at lower MDA5 
concentrations. Presence of the V protein caused a strong accumulation of the faster migrating species 
irrespective of whether the first incubation step of MDA5 was performed with RNA or V protein. One 
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plausible explanation for the observed alteration in migration is that V protein binding interferes with the 
cooperative RNA-binding mode of MDA5. The three-dimensional reconstruction of RNA-bound MDA5 
filaments by electron microscopy showed that MDA5 uses intermolecular contacts which involve all three 
subdomains of the SF2 ATPase domain to assemble along dsRNA (61) (see also section 1.3.2 and figure 
6). In absence of the V protein, suchlike interactions could allow cooperative binding of two MDA5 
molecules to the 24bp RNA-ligand resulting in one major, slowly migrating species. As V protein binding 
is assumed to disrupt the fold of the MDA5 SF2 ATPase domain, cooperative binding via intermolecular 
contacts of the ATPase subdomains might be hindered in presence of the V protein. The isolated MDA5 
RD has been shown to bind RNA independently from the SF2 ATPase domain (56, 59). According to the 
crystal structure of the ssMDA5:PIV5 V protein core complex, this domain seems not to be affected by V 
protein binding. In presence of the V protein, an intact RD could allow MDA5 molecules to bind non-
cooperatively to the ends of the dsRNA-ligand resulting in a mixture of fast migrating 1:1 and slowly 
migrating 2:1 MDA5:dsRNA complexes (see figure 33B).  
 
A
B
 
 
Figure 36: (A) Electrophoretic mobility shift assays (EMSAs) of mmMDA5 incubated with palindromic 24bp RNA 
(1 µM final) in absence and presence of PIV5 V protein. Incubation of mmMDA5 with dsRNA after or before 
addition of PIV5 V protein does not change the observed pattern in migration. The fast migrating species is 
indicated by a star. (B) Models of possible MDA5:dsRNA species observed in EMSAs in absence and presence of 
paramyxoviral V protein. Model for cooperative binding as described in (54, 61).   
 III RESULTS  
  65 
 Superposition of the C-terminal zinc binding motif and the MDA5:RNA clamp structure (see 
figure 37A) illustrates that wedging of the CTD into the SF2 ATPase domain disrupts structural patterns 
that are essential for binding of RNA and required for the formation of a proper MDA5:MDA5 interface 
within RNA-bound filaments (61) (see also section 1.3.2). To directly prove that V protein binding indeed 
interferes with the cooperative RNA-binding mode of MDA5, filament formation of full length MDA5 
was analyzed in absence and presence of V protein employing electron microscopy. Figure 37B shows 
negatively stained filaments formed by purified mmMDA5 on poly(I:C). The presence of PIV5 V protein 
drastically reduced the number of filaments independent from the absence or presence of ATP. Thus, the 
paramyxoviral V protein is able to affect both, the ATPase activity as well as the cooperative RNA-
binding activity of MDA5.  
 
 
 
 
VCTD
MDA5 CRecA
MDA5 RD
MDA5 NRecA
MDA5 
Insertion 
A B
 
Figure 37: (A) Structure of human CARDless MDA5 in complex with dsRNA (PDB code: 4GL2) with 
superimposed PIV5 V
CTD
 (dot density shown in orange and modeled from the position in the ssMDA5:PIV5 V 
protein complex). The subdomains of the MDA5 SF2 ATPase domain are shaded in blue, the RD is shown in red 
and the dsRNA-ligand in grey. (B) Filament formation of mmMDA5 on poly(I:C) visualized by negative-stain 
electron microscopy in the presence and absence of ATP and PIV5 V protein. Shown are representative grid areas.  
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4. Discussion  
 
4.1 A structure-derived model for MDA5 inhibition by paramyxoviral V proteins 
The integration of the findings presented in this thesis with the current state of knowledge in the field of 
RLR function and signaling allows us to derive of a first molecular mechanism for the inhibition of the 
innate immune receptor MDA5 by paramyxoviral V proteins (see figure 38). In the absence of V protein, 
MDA5 is able to hydrolyze ATP and to cooperatively assemble into filaments along viral dsRNA (13, 30, 
53, 54, 61) (see also section 1.2.1). This ensures the formation of an intact and functional signalosome 
that involves homotypic CARD-CARD interaction with the signaling adaptor protein MAVS and its 
polymerization into fibrils on the mitochondrial membrane (30, 67-73) (see also section 1.4.1). The 
MDA5-MAVS signaling entity is believed to be crucial for the activation of pathways that finally induce 
an antiviral state of the host cell (4, 5, 66, 76, 77, 79) (see also section 1.4.2).  
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RDMDA5
 
 
Figure 38: Proposed model for inhibition of MDA5 signaling assemblies by paramyxoviral V proteins. The dsRNA-
bound MDA5 filaments are assumed to interact with MAVS and induce the formation of MAVS fibrils postulated to 
be active signal-entities (30, 67-73). The V protein disrupts the architecture of the MDA5 SF2 ATPase domain by a 
β-strand replacement mechanism and is assumed to unfold itself in the process of MDA5 binding. V protein-induced 
partial unfolding of MDA5 results in disruption of functional MDA5:dsRNA filaments and hence signal-
transmission of the antiviral response. The structure and interactions of the NTD in the MDA5 complex are only 
illustrated and need to be addressed in future studies. Model for cooperative RNA binding by dsMDA5 as described 
in (54, 61).  
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 The structural determination of the conserved MDA5:V protein complex (131, 134-136) revealed 
that paramyxoviral V proteins are able to trap MDA5 in an inactive state by disrupting its SF2 ATPase 
domain. The V protein inserts its C-terminal zinc binding motif into the central β-sheet of the MDA5 C-
terminal RecA-like fold and displaces its canonical β-strands 1 and 6 (see section 3.4). This partial 
unfolding of the innate immune receptor abolishes its ATPase activity and simultaneously disturbs 
cooperative filament formation on dsRNA presumably by breaking up the MDA5:MDA5 interface (54, 
61) as well as the MDA5:dsRNA interface (30) (see section 3.7). It has been shown that ATP hydrolysis 
and filament formation by MDA5 have to go hand in hand to assemble a functional MDA5-MAVS 
signalosome and to trigger downstream signaling cascades that limit viral replication (5, 30, 66, 78, 83-
86) (see also sections 1.3 and 1.4). Targeting both activities, the paramyxoviral V protein represents a 
very potent inhibitor of MDA5 that can antagonize MDA5-mediated host immune response at the very 
first step of viral ligand recognition. Unlike in the case of paramyxoviral inhibition of common 
downstream TLR/RLR signaling components (e.g. IKKε/TBK1, NF-κB, IRF3 and IRF7, STAT1 and 
STAT2; see also figure 6 and section 1.5.2), this enables the V protein to avoid amplification of the signal 
during the transduction cascade and hence efficient repression of MDA5 pathways.  
 Experiments examining the activation of a interferon-β promoter responsive to the transcription 
factors AP-1, NF-κB, IRF-3 and IRF-7 (153) by human MDA5 in living cells emphasize the importance 
of MDA5 as target for paramyxoviral V proteins (see figure 39). In these gene reporter assays, the 
signaling activity of wild type hsMDA5 was found to be almost completely inhibited in the presence of 
wild type MV V protein, whereas the E235A
MV
 mutant caused a distinct attenuation of the signaling 
inhibition (see figure 39A and also (131)). This mutant was observed to be impaired in its interaction with 
MDA5 in living cells (see figure 43 and also (131)) as well as in analytical size exclusion 
chromatography experiments (see figure 31A with the equivalent E174A
PIV5
 mutant), indicating  that the 
partial reconstitution of the MDA5 signaling pathway seen in the interferon-β promoter dependent gene 
reporter assays is caused by restricted binding of the V protein mutant to MDA5. Similar reduction of V 
protein-mediated inhibition of interferon-β promoter activity could be obtained with the structure-derived 
R806L
hsMDA5
 mutant (see figure 39B), which was shown to be able to evade V protein recognition in 
living cells (see figure 43) as well as in vitro (see figure 31A with the equivalent R806L
mmMDA5
 mutant). 
The measured degree of the partial rescue obtained with the R806L
hsMDA5
 mutant was not found be 
enhanced in the presence of the E235A
MV
 mutant. This positive control verifies that the observed 
reconstitution of the MDA5 signaling pathway indeed results from impaired MV V protein binding to 
R806L
hsMDA5
. The incomplete rescue of the MDA5 signaling activity in both experiments is most likely 
the consequence of the multifunctionality of the V protein, which is known to inhibit the induction of 
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interferon-β at several levels (e.g. at the level of the IRF3/7 activating kinase IKKε/TBK1 and at the level 
of the transcription factors IRF3/7 as well as NF-κB) (109, 111-114) (see also section 1.5.2 and figure 6).  
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Figure 39: Attenuation of V protein mediated MDA5 signaling inhibiton by mutation of the conserved salt bridge 
within the MDA5:V protein interface (57) (data of Dr. Kerstin Monika Schuhmann and Prof. Karl-Klaus 
Conzelmann, Gene Center Munich). Shown are interferon-β promoter dependent luciferase reporter gene assays 
performed in HEK-293T cells with a promoter sequence, which is responsive to the transcription factors AP-1, NF-
κB, IRF-3 and IRF-7 (153). Mean values (+/- SEM) were obtained from experiments performed in triplicate (N=3). 
Expression levels of transfected flag-tagged hsMDA5 and MV V protein plasmids were analyzed by western blot 
(lower panels). (A)  Reporter gene assay performed with hsMDA5 WT and MV V WT or MV V E235A. Shown are 
relative values of the interferon-β promoter activity related to the MDA5 WT value (100%). (B) Reporter gene assay 
performed with hsMDA5 R806L and MV V WT or MV V E235A. Shown are relative values of the interferon-β 
promoter activity related to the MDA5 R806L value (100%).  
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4.1.1 Which energy source drives the unfolding processes that accompany V protein binding?  
Provided that the PIV5 V protein structure observed within the DDB1 complex (104) (see also sections 
1.5.1 and 4.4) is stable in absence of a binding partner as well, the V protein has to unfold itself to allow 
disruption of the MDA5 SF2 ATPase fold (see section 3.6). According to this structure, the insertion of 
the viral C-terminal zinc binding motif (CTD) into the C-terminal RecA-like fold of MDA5 and 
formation of the MDA5:V protein interface requires not only abrogation of intermolecular interactions 
within the MDA5 molecule but also within the PIV5 V protein (see figure 32). This raises the question 
which energy source actually drives the unfolding processes postulated in this thesis. Differential 
scanning fluorimetry experiments suggest that a significant gain in thermostability might favor 
complexation of MDA5 and the PIV5 V protein (see figure 34). The experiments revealed that the 
melting temperature of isolated MDA5 in presence of the V protein ligand increases by approximately 
10°C indicating that the formation of a highly stable MDA5:V protein core could compensate and 
outbalance the presumed unfolding processes. The thermal shift assays further revealed that the PIV5 V 
protein itself is not very stable as it did not show a reasonable transition midpoint of protein unfolding 
(see figure 34A). This finding argues for an undefined and transient tertiary structure of the PIV5 V 
protein and makes doubt that the structure observed within the DDB1 complex represents a stable 
conformation. This observation leads to the question whether V protein binding to MDA5 involves an 
induced fit mechanism of the viral N-terminal domain (NTD). The NTD of the PIV5 V protein is not 
present in the determined crystal structure of the ssMDA5:PIV5 V protein core complex, probably 
because it adopts the unfolded conformation seen in P protein (106) and its flexibility caused  proteolytic 
cleavage during the crystallization process (see sections 3.3 and 3.4). However, the possibility that the 
NTD of the PIV5 V protein binds to MDA5 portions, which are missing in the crystal structure (namely 
CARDs, N-terminal RecA-like fold and RD), and thereby undergoes structural stabilization via an 
induced fit mechanism cannot be ruled out. As the PIV5 V protein has been shown to be able to bind the 
isolated N-terminal RecA-like fold of MDA5 in yeast two-hybrid assays (136) (see also section 1.5.2), 
this might represent a reasonable scenario. Analysis by NMR might be suitable to gain further insight into 
the nature of potential MDA5:V protein interactions that defied crystallization and possible associated 
induced fit or unfolding processes. Hydrogen-deuterium exchange might allow to compare the solvent 
accessibility of different protein parts in isolation and within the complex and hence to complement the 
MDA5:V protein binding mode presented in this thesis.  
 Moreover, it has to be considered that the observed and described gain in MDA5’s 
thermostability refers to monomeric MDA5 proteins in an RNA-unbound state, but not to cooperatively 
assembled, RNA containing MDA5 filaments (see figure 34). In this context it would be interesting to 
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know,  how the inhibition of MDA5 by paramyxoviral V proteins actually proceeds in vivo. It has not yet 
been fully elucidated if the V protein already exists within the virion and enters the host cell with the viral 
ribonucleoprotein (RNP) complex or if it is produced later during viral replication within the host cell (98, 
102). The first scenario would allow instant prevention of MDA5 filament formation on viral dsRNA 
ligands by paramyxoviral V proteins and therefore efficient inhibiton of MDA5 mediated antiviral 
signaling. The second scenario raises the question, if paramyxoviral V proteins possess the capability to 
dissolve already formed and robust MDA5 filaments. The EMSA experiments presented in this thesis (see 
section 3.7 and figure 36) indicate that V proteins might be able to remove MDA5 proteins from dsRNA. 
However, if the actual in vivo situation, in which MDA5 filaments might be stabilized or protected by 
other protein factors or specific subcellular localization (e.g. formation of cytoplasmic foci or docking to 
MAVS at the outer mitochondrial membrane (30, 67-73) (see also section 1.4.1)), allows such a process 
requires further investigation and better understanding of MDA5 filament assembly and signaling in vivo.  
 
 
4.1.2 Known β-strand displacement mechanisms in other biological processes 
The regard of other known β-strand displacement mechanisms might contribute to improved 
comprehension of the complexation process between MDA5 and the V protein. A well studied β-strand 
displacement mechanism is the chaperone-assisted assembly of adhesive pili on the surface of gram-
negative bacteria (see figure 40). These bacteria use their general secretory pathway to export pilus 
subunits (pilins) to the periplasm, where they are captured and stabilized by SafB chaperones. Pilins adapt 
an immunoglobulin-like (Ig-like) fold that lacks the seventh, C-terminal β-strand and thus exhibit an 
exposed hydrophobic groove on its surface. The SafB chaperone assists pilins in folding by providing the 
missing β-strand in trans. The donor-strand of the chaperone shields the hydrophobic groove, 
complements the Ig-like fold and simultaneously prevents premature polymerization of pilin subunits by 
occupying their interaction surface. Pilus assembly requires the formation of a transient ternary complex 
that involves the chaperone:pilin complex and the N-terminal β-strand of an incoming pilin subunit. In the 
course of the polymerization reaction, the donor-strand of the chaperone is replaced by the N-terminal β-
strand of the next pilin subunit (154). This donor-strand exchange process was shown to proceed 
spontaneously in vitro (155) and to occur in vivo at the outer membrane of gram-negative bacteria 
independent from the presence of an energy source (156). The chaperone primes the pilin protein for a 
topological transition that drives pilin polymerization into fibers. The bound chaperone keeps the 
hydrophobic groove of the pilin subunit in an open, activated conformation. During the exchange of the 
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donor strand, the pilin subunit closes the groove and seals the N-terminal β-strand of the next subunit in 
place (155).  
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Figure 40: Structural comparison of the pilin subunit (shown in blue) in complex with the SafB chaperone (shown 
in yellow) (left panel, PDB code: 2CO6) and in complex with the N-terminal β-strand of an adjacent pilin subunit 
(show in orange) of the pilus fibre (right panel, PDB code: 2CO4). Adapted from (154).  
  
 
 
 Structural work on serpins (serin protease inhibitors) revealed tremendous and irreversible 
conformational changes during their mechanism of action that involves a β-strand insertion. Serpins 
represent covalent “suicide” protease inhibitors and therefore crucial regulators of many and diverse 
biological processes. Serpins expose a reactive center loop (RCL) that provides a “bait” peptide bond for 
serine proteases (see figure 41). The nucleophilic attack by the serine residue of the catalytic triade 
located in the active site of the protease leads to the formation of a covalent complex between inhibitor 
and protease. The cleaved and now unconstrained RCL is inserted into a central β-sheet of the serpin 
protein and thereby traps the covalent complex. Similar to V protein-bound MDA5, the RCL-cleaved 
form of serpin inhibitors shows a significant higher thermostability as the native, uncleaved state 
indicating a global stabilization of the serpin protein within the covalent complex and explains why an 
active inhibitor cannot be recovered without providing energy (157).  
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Figure 41: (A) Crystal structure of an active serpin (shown in blue). The inhibitory reactive center loop (RCL) is 
indicated by an arrow (PDB code: 1QLP). (B) Crystal structure of a covalent serpin:protease complex. The protease 
is shown in yellow, serpin in blue and the cleaved and inserted RCL in orange (PDB code: 1EZX). Adapted from 
(157-159).  
 
 
4.2 Is the RD of RLRs able to switch between two binding modes?  
The V protein-induced disappearance of any filamentous structures of MDA5 on long dsRNA in EM 
experiments on the one hand, but clear binding of MDA5 to a short 24bp RNA ligand in EMSA 
experiments in the presence of the SF2 disruptive V protein on the other hand (see figures 37 and 36), 
raise the question if the MDA5 RD is able to switch between dsRNA stem recognition and dsRNA end 
recognition. The crystal structure of the MDA5 RNA clamp revealed that the MDA5 SF2 ATPase domain 
fixes dsRNA stem recognition by the MDA5 RD directly and indirectly (30) (see also section 1.3.2). In 
contrast, a conserved loop within the RIG-I RD mediates its binding to dsRNA ends (26, 29, 46) (see also 
sections 1.2.2 and 1.3.1). The equivalent loop of the MDA5 RD within the RNA clamp structure was 
found to be disordered due to displacement by the stem of the dsRNA ligand (30). However, the loop 
region of the free and isolated MDA5 RD is ordered and adopts a similar conformation as seen for the 
loop region of the RIG-I RD in the dsRNA-bound state (see figure 42) (30, 56). This observation implies 
that the MDA5 RD might have the potential to switch between two different dsRNA-binding modes. 
Moreover, the MDA5 RD loop is well conserved in sequence among MDA5 orthologs suggesting as yet 
undefined function of this region. 
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 It has further been shown that RIG-I is able to translocate along dsRNA upon recognition of 
dsRNA ends (62), supporting the idea of plasticity of RD mediated dsRNA-binding. It would be 
interesting to address the question of different RD binding modes in further experiments and to elucidate 
possible functional impacts on RLR-mediated ligand sensing and antiviral signaling efficiency.  
 
RD loop
 
 
Figure 42: Superposition of the RNA-free MDA5 RD structure (shown in blue, PDB code: 3GA3) and the RNA-
bound RIG-I RD structure (shown in yellow, PDB code: 3TMI) reveals similar conformation of the RD loop. 
Adapted from (29, 30, 56).  
 
 
4.3 V protein binding to other RLR family members and its functional impact 
The crystal structure of the ssMDA5:PIV5 V protein core complex and in vitro validation experiments of 
the interface revealed a crucial role of salt bridge formation between a conserved arginine residue of 
MDA5 (that is missing in case of RIG-I) and a conserved glutamate residue of paramyxoviral V proteins 
for complexation (see section 3.5 and figures 30 and 31A). Consistent with these findings are results of 
co-immunoprecipitation experiments using flag-tagged hsMDA5 and MV V protein overexpressed in 
living cells (see figure 43, left panel) (57). Mutating R806
hsMDA5 
(equivalent to R803
ssMDA5
) to a leucine 
residue (as found in RIG-I) reduced the interaction between hsMDA5 and MV V protein. Likewise, 
mutating E235
MV 
(equivalent to E174
PIV5
) strongly reduced binding to hsMDA5 in living cells. These data 
verify the demonstrated importance of both sides of the salt bridge for MDA5:V protein complexation 
(see figure 31A). The in vitro experiments presented in section 3.5 and these co-immunoprecipitation 
experiments validate the MDA5:V protein interaction observed in the crystal structure (see figure 30A) 
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with proteins of four different species (mmMDA5, hsMDA5, PIV5 V protein, MV V protein) and 
therefore confirm evolutionary conservation of the binding mode.  
 
Figure 43: Western-blot analysis of co-immunoprecipitation experiments performed with flag-tagged hsMDA5 or 
hsRIG-I and MV V protein expressed in HEK-293T cells (57) (data of Dr. Kerstin Monika Schuhmann and Prof. 
Karl-Klaus Conzelmann, Gene Center Munich). EV = empty vector. Left panel: Mutations affecting the salt bridge 
formation between the conserved glutamate of V protein and arginine of MDA5. Right panel: Mutation(s) of RIG-I 
to mimic the critical MDA5 arginine.  
 
 
 Moreover, the induced in vitro binding of PIV5 V protein to the structure-derived L715R 
E717G
mmRIG-I
 mutant that mimics the critical MDA5 arginine residue (see section 3.5 and figure 31B) was 
validated in living cells by co-immunoprecipitation experiments using flag-tagged hsRIG-I and MV V 
protein (see figure 43, right panel) (57). In these experiments, the single exchange of L714
hsRIG-I  
with 
MDA5’s arginine was found to be sufficient to induce binding of MV V protein to hsRIG-I. The double 
mutant L714R E716G
hsRIG-I 
(the second mutation accounts for the likely clash between a conserved 
tryptophan residue of the V protein and the glutamate that RIG-I has instead of the glycine found in 
MDA5, see also section 3.5 and figure 30) strengthens the observed interaction. This induced interaction 
was found to be in turn abolished by the E235A
MV
 mutant. These data confirm that a different residue 
conservation within the C-terminal RecA-like fold of RIG-I enables this RLR family member to evade 
binding by paramyxoviral V proteins (134)  (see also section 1.5.3) and that structure-guided exchange of 
only two amino acids is able to annul this evasion (see also section 3.5).   
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4.3.1 Engineering of RIG-I inhibition by paramyxoviral V proteins  
The question arises if the structural model presented in this thesis describes the recognition of MDA5 by 
V proteins sufficiently well to allow engineering not only of robust binding to V proteins into RIG-I but 
also V protein mediated inhibition of the RIG-I signaling activity in living cells. Figure 44 shows the 
activation of the interferon-β promoter by stimulated wild type hsRIG-I and the structure-derived hsRIG-I 
mutants that mimic the MDA5 interface required for V protein binding. The reporter gene assays revealed 
that signaling mediated by wild type hsRIG-I is partially inhibited in presence of the wild type MV V 
protein as well as by the E235A
MV
 mutant (see figure 44A). Wild type RIG-I was shown not to bind to the 
paramyxoviral V protein, neither in vitro (see figure 31B) nor in living cells (see figure 43). The observed 
partial inhibition of RIG-I signaling is probably caused by the multifunctionality of the V protein, which 
was shown to inhibit the induction of interferon-β at several levels (109, 111-114) (see also section 1.5.2 
and figure 6).  
 The gene reporter assays performed with the L714R
hsRIG-I 
mutant and wild type MV V protein or 
E235A
MV
 mutant demonstrated similar results as for the wild type hsRIG-I protein (see figure 44B). The 
L714R
hsRIG-I 
mutant has been shown to bind the MV V protein in living cells (see figure 43), but not the 
PIV5 V protein in size exclusion chromatography experiments (see figure 31B with the equivalent 
L715G
mmRIG-I
 mutant). However, the measured degree of L714R
hsRIG-I 
signaling inhibition in presence of 
wild type MV V protein is comparable to wild type hsRIG-I and was not found to be attenuated in 
presence of the E235A
MV
 mutant, indicating the L714R
hsRIG-I 
single 
 
mutant is not sensitive to an 
inhibition induced by binding of the MV V protein. The E335A
MV
 mutant was shown to abolish the 
induced V protein interaction of the engineered L714R
hsRIG-I  
mutant in living cells (see figure 43) and 
serves therefore as a control in this experiment.  
 In comparison to the experiments performed with wild type hsRIG-I or with the L714R
hsRIG-I 
mutant, the gene reporter assays examining the L714R E716G
hsRIG-I 
mutant illustrate a distinct drop of 
its signaling activity in presence of wild type MV V protein (see figure 44C). This finding implies that the 
RIG-I double mutant is responsive to inhibition induced by MV V protein binding. The RIG-I double 
mutant has been shown to bind paramyxoviral V proteins in living cells (see figure 43) as well as in in 
vitro size exclusion chromatography experiments (see figure 31B with the equivalent  L715R 
E717G
mmRIG-I
 mutant). Unlike in the case of the L714R
hsRIG-I 
mutant, the decrease of the signaling 
activity seen for the L714R E716G
hsRIG-I
 mutant was found be released in presence of the E235A
MV
 
mutant. This control experiment verifies that the observed drop in signaling activity can be indeed 
ascribed to recognition of the RIG-I double mutant by the MV V protein and demonstrates that the 
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structure-derived model of MDA5 inhibition is sufficient to engineer not only binding, but also inhibition 
by paramyxoviral V proteins into RIG-I.  
 
 
Fig. 44: Signaling inhibition of wild type hsRIG-I or engineered RIG-I mutants (that mimic the MDA5 interface 
required for V protein binding) by MV V protein (unpublished data of Dr. Kerstin Monika Schuhmann and Prof. 
Karl-Klaus Conzelmann, Gene Center Munich). Shown are interferon-β promoter dependent luciferase reporter gene 
assays performed in HEK-293T RIG-I knock out cells with a promoter sequence which is responsive to the 
transcription factors AP-1, NF-κB, IRF-3 and IRF-7 (153). Mean values (+/- SEM) were obtained from experiments 
performed in triplicate (N=3). Expression levels of transfected flag-tagged hsRIG-I (wild type or mutants) and MV 
V protein (wild type or mutant) plasmids were analyzed by western blot (lower panels). Flag-tagged hsRIG-I (wild 
type or mutants) was stimulated using Sendai virus defective-interfering genomes (SeDI) (160). (A) Reporter gene 
assay performed with wild type hsRIG-I and MV V WT or MV V E235A. Shown are relative values of the 
interferon-β promoter activity related to the RIG-I WT value (100%). (B) Reporter gene assay performed with 
hsRIG-I L714R and MV V WT or MV V E235A. Shown are relative values of the interferon-β promoter activity 
related to the RIG-I L714R value (100%). (C) Reporter gene assay performed with hsRIG-I L714R E716G and MV 
V WT or MV V E235A. Shown are relative values of the interferon-β promoter activity related to the RIG-I L714R 
E716G value (100%).  
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 The leucine and glutamate residue within the fifth β-strand of the RIG-I C-terminal RecA-like 
fold allows RIG-I to avoid recognition and inhibition by paramyxoviral V protein, but that alone does not 
explain the strict conservation of these two residues among RIG-I orthologs (see figure 30B). This raises 
the question of the actual function of the divergent residue conservation observed in MDA5 (R and G) 
and RIG-I (L and E). The comparison of the absolute activities of wild type MDA5 and the MDA5 
mutant as well as wild type RIG-I and RIG-I mutants (see figure 45) measured in the described luciferase 
reporter gene assays (see figures 39 and 44) imply that these residues might play a role in the activity 
regulation of RIG-I like receptors. The MDA5 mutant, whose arginine is replaced by RIG-I’s leucine, 
exhibits significantly higher activity than the unmodified wild type protein (see figure 45, right panel). 
Vice versa, the RIG-I double mutant, whose leucine and glutamate is replaced by MDA5’s arginine and 
glycine, shows reduced activity compared to wild type RIG-I (see figure 45, left panel). It seems possible 
that these residues contribute to the communication between the different domains within the RNA clamp 
structure during the ATP hydrolysis cycle. Detailed elucidation of the course of action at the atomic level 
might give helpful insights into evolutionary constraints that underlie the distinct residue conservation 
within the SF2 ATPase domain or RLRs (see also section 1.3). 
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Figure 45: Left panel: Absolute activity of wild type hsMDA5 and the hsMDA5 R806L mutant measured in 
interferon-β promoter dependent luciferase reporter gene assays performed in HEK-293T cells (see also figure 39). 
Right panel: Absolute activity of SeDI stimulated wild type hsRIG-I, the hsRIG-I L714R mutant and the hsRIG-I 
L714R E716G double mutant measured in Interferon-β promoter dependent luciferase reporter gene assays 
performed in HEK-293T RIG-I knock out cells (see also figure 44). (Unpublished data of Dr. Kerstin Monika 
Schuhmann and Prof. Karl-Klaus Conzelmann, Gene Center Munich).  
 IV DISCUSSION  
  78 
4.3.2 Indirect inhibition by paramyxoviral V proteins via LGP2 
Co-immunoprecipitaton experiments have shown that MDA5 and LGP2 share the interactive site that 
mediates interference by paramyxoviral V proteins (135). Indeed, the LGP2 SF2 ATPase domain is able 
to form a stable, stoichiometric complex with the PIV5 V protein in size exclusion chromatography (see 
figure 30C). The arginine as well as the glycine residue identified to be critical for V protein binding by 
MDA5 are also conserved among LGP2 orthologs (see figure 30B). This implies similar interactions 
within the LGP2:V protein complex as seen for the ssMDA5:PIV5 V protein interface. It was further 
suggested that V protein binding to LGP2 mediates indirect inhibition of RIG-I by promoting the 
formation of inactive complexes between LGP2 and RIG-I (161). In addition, studies on LGP2 knockout 
mice let assume that LGP2 might function as a positive regulator of both MDA5 as well as RIG-I 
signaling (19) (see also section 1.4.3). Binding of paramyxoviral V proteins to LGP2 could affect this 
positive regulation of MDA5 and RIG-I during viral infection. However, to answer the question how the 
interaction of V proteins with LGP2 might contribute to an inhibition of MDA5 and RIG-I and to judge 
its impact on antiviral processes, requires detailed analysis of the actual function of LGP2 in RLR 
mediated signaling at the molecular level. In this context, it would be interesting to know if the LGP2 
molecule itself is able to assemble into filamentous structures along viral RNA ligands and/or supports 
MDA5 filament formation in vivo.  
 
4.3.3 Viral pressure on the evolution of RLRs 
Orthologs of MDA5, but not of RIG-I, exist in fish, indicating that MDA5 might have evolved before 
RIG-I (162). Furthermore, the absence of RIG-I in chicken is assumed to cause their increased 
susceptibility to influenza viruses (163). RIG-I has been shown to be the main PRR known for detecting 
influenza virus infection as well as infections by various members of the Paramyxoviridae family in 
mammalian cells (see also section 1.2) (14, 32-34). These findings let speculate that RIG-I might have 
evolved in higher organism to ensure efficient recognition and defense of virus species that are able to 
successfully defy sensing by MDA5, for instance through its inhibition by V proteins. It would be 
exciting to elucidate in detail how evolutionary pressure imposed by viruses directed the diversification of 
core functional domains of RLRs, which appears to be fundamental for a powerful viral surveillance 
system in vertebrates (see also sections 1.2 and 1.3).  
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4.4 The paramyxoviral V protein as a universal immune targeting tool  
Numerous studies have shown that the V protein represents a pivotal element in immune evasion 
strategies of paramyxoviruses. This protein attacks not only the MDA5 signaling pathway by directly 
targeting MDA5 (see section 4.1), but also antagonizes common host factors of central immune pathways 
to severely disturb production as well as signaling of immunostimulating cytokines (see also section 1.5 
and figure 6). Among these targets are the IKKε/TBK1 kinase that activates the transcription factors IRF3 
and IRF7 in TLR as well as in RLR signaling cascades (114), but also IRF3 and IRF7 themselves (111, 
113). Interference with the NF-kB family member p65 completes the inhibitory capacity of paramyxoviral 
V proteins for TLR and RLR signaling pathways at the transcriptional level (109). All these activities of 
the paramyxoviral V protein are directed against the induction of antiviral cytokine production, but the 
protein is also able to affect the paracrine and autocrine signaling system of cytokines either by direct 
inhibition of STAT transcription regulators or by mediating their proteasomal degradation (104, 115-
129).  
 The paramyxovirally induced degradation of STAT proteins requires binding of the V protein to 
DDB1 (120). DDB1 acts as a substrate recruiting adaptor protein within the DDB1-Cul4A ubiquitin 
ligase machinery that normally functions in the regulation of DNA repair, DNA replication and 
transcription (104, 125). The V protein of mumps virus, PIV5 and hsPIV2 has been shown to capture 
DDB1 to exploit the ubiquitin ligase activity of the DDB1-Cul4A complex for STAT degradation (118, 
119, 122). Structural determination of the PIV5 V protein bound to DDB1 revealed the molecular basis 
for this viral hijack (see figure 46) (104). In this complex, the PIV5 V protein was found to use an N-
terminal α-helical motif to interact with a β-propeller of DDB1 (BPC in figure 46). The PIV5 V protein 
inserts its helix into the binding pocket of the β-propeller that is usually responsible for the docking of 
DCAFs (DDB1-Cul4-associated factors) receptors, which mediate selective recruitment of specific 
substrates for ubiquitination by the DDB1-Cul4A E3 machinery (164). The C-terminal zinc binding motif 
(CTD) is not directly involved in the interaction with DDB1, but shielded by the NTD of the protein (104) 
(see also section 3.6). However, a tryptophan-rich motif within the CTD of paramyxoviral V protein has 
been assumed to provide association with various STAT proteins (123, 124, 165). In this way, the V 
protein could function as a bipartite adaptor that allows recruitment and presentation of STAT proteins to 
the DDB1-Cul4A ubiquitin ligase machinery to subvert its function to benefit viral replication.  
 The CTD of paramyxoviral V proteins is not only involved in binding of STAT factors and 
MDA5, but has also been shown to be sufficient for the interaction with the transcription factors IRF7 and 
p65 (109, 113). Such findings imply that paramyxoviruses use their conserved CTD as a general binding 
module with various, but distinct destinations (e.g. MDA5 and LGP2 but not the third RLR family 
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member RIG-I, p65 but not the highly related p50 protein) to simultaneously counteract multiple major 
pathways of the innate immune system. Further structural analysis of the V protein in complex with 
different targets is required to reveal the impact of its versatility in detail and to deepen our knowledge of 
virus-host interactions and the evolutionary adaption of viral immune evasion strategies.  
 
 
 
 
Figure 46: Crystal structure of the PIV5 V protein (shown in grey) in complex with DDB1 (shown in blue) with 
indicated functions of its β-propellers (BP) A, B and C (PDB code: 2B5L). The N-terminal α-helical motif that the 
PIV5 V protein uses to bind to the BPC and thus to subvert the function of DDB1 as substrate recruiting adaptor 
protein within the DDB1-Cul4A ubiquitin ligase machinery is highlighted in orange. Adapted from (104, 125).  
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5. Summary  
 
The innate immune system represents a universal first line defense of the host. It plays a crucial role in the 
early recognition of microbial pathogens and subsequent triggering of signaling cascades, which induce 
the defense reactions of the host cell during infection. To achieve this task, the innate immune system is 
armed with a large family of membrane-bound as well as cytoplasmic receptor proteins. These pattern 
recognition receptors (PRRs) mediate sensing of particular molecular signatures on pathogens called 
pathogen-associated molecular patterns (PAMPs). The specific interaction of the receptor molecule and 
its ligand allows the immune system to distinguish infectious nonself from noninfectious self.  
 The RIG-I like receptors (RLRs) RIG-I, MDA5 and LGP2 are key sentinels in the detection of 
viruses. They function as cytoplasmic PRRs by binding to viral RNAs during virus infection. The 
members share a modular domain organization composed of N-terminal tandem caspase activation and 
recruitment domains (CARDs) (which are absent in LGP2), a central superfamily 2 (SF2) ATP hydrolysis 
domain, and a C-terminal RNA binding domain (RD). Structural studies demonstrated that the RD and 
SF2 ATP hydrolysis domain of RIG-I as well as MDA5 act in concert to efficiently sense viral RNAs. 
They were found to form a RNA clamp structure, which encircles the viral dsRNA from all sites. This 
ring formation triggers the release or oligomerization of the CARDs and thereby transmission of the 
signal via a pathway that involves the interaction with the mitochondrial signaling adaptor protein 
MAVS. The initiated signal cascade leads finally to the activation of transcription factors such as IRFs 
and NF-κB, which control the production of type I interferons and other proinflammatory cytokines. 
Thus, RLRs play a central role in the induction of an antiviral state of the host cell.  
 Viruses have evolved numerous mechanisms to antagonize the host immune response. The family 
of paramyxoviruses produce the V protein, which specifically binds and inactivates MDA5, but not    
RIG-I. The highly conserved C-terminal domain (CTD) of these V proteins is known to fold into a unique 
zinc binding motif. Several studies showed that the integrity of this motif is required for binding and 
inhibition of the MDA5 ATP hydrolysis domain.  
 This thesis presents the crystal structure of the evolutionary conserved core of the MDA5:V 
protein complex and describes a first molecular mechanism of how a viral inhibitor protein targets an 
RLR signaling component. The structure of the Parainfluenza virus 5 (PIV5) V protein in complex with 
MDA5 revealed that paramyxoviral V proteins use their conserved CTD to integrate themselves into the 
ATP hydrolysis domain of MDA5. In detail, the V protein melts into the central β-sheet of the C-terminal 
RecA-like fold of MDA5 and displaces its canonical β-strands 1 and 6 by the two β-strands of the CTD. 
This partial unfolding of the MDA5 structure allows V proteins to trap MDA5 in an inactive state.  
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 The wedging of the viral CTD into the C-terminal RecA-like fold was found to disrupt the 
conserved motif VI, which MDA5 shares with all other members of the SF2 helicase family and is known 
to be essential for ATP binding and hydrolysis. This explains how V proteins shut down the ATP 
hydrolysis activity of MDA5. Simultaneously, the insertion of the viral CTD causes a disruption of 
structural patterns within the SF2 ATP hydrolysis domain, which are required for the formation of the 
RNA clamp structure and hence for binding and proper sensing of viral RNA ligands by MDA5. As a 
consequence, the MDA5 protein was found to be unable to assemble into long filaments along viral 
dsRNA in the presence of the V protein. Cooperative filament formation of MDA5 on long dsRNA is a 
hallmark of this immune receptor and has to go hand in hand with ATP hydrolysis to ensure the assembly 
of a functional and active MDA5:MAVS signalosome, which finally triggers downstream pathways that 
limit viral replication. Targeting both, the ATPase as well as the RNA binding activity of MDA5, the 
paramyxoviral V protein represents a very potent inhibitor that can antagonize MDA5 mediated host 
immune response at the very first step of ligand recognition.  
 The structure of the MDA5:V protein core complex also explains why MDA5 is recognized by 
MDA5, but not the highly related RIG-I. The MDA5:V protein interface as well as binding studies 
revealed that the formation of a stable complex relies on a salt bridge between a highly conserved 
arginine residue within the C-terminal RecA-like fold of MDA5 and a highly conserved glutamate residue 
within the CTD of paramyxoviruses. RIG-I lacks the conserved arginine residue and has instead a 
conserved leucine residue at this position that provides no anchoring point for salt bridge formation with 
the viral glutamate residue. This difference in residue conservation allows RIG-I proteins to evade 
recognition and hence inhibition by paramyxoviral V proteins.  
  In conclusion, the structural and biochemical data presented in this thesis provide important 
mechanistic insights into the inhibition of MDA5 by paramyxoviral V proteins and enhances our 
knowledge of virus-host interactions and the evolutionary adaption of viral immune evasion strategies.  
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AIM2  -  absent in melanoma 2      
ASC  -  apoptosis-associated speck-like protein containing a CARD 
ATP  -  adenosintriphosphate 
Bis-Tris  -  bis(2-hydroxyethyl)amino-tris(hydroxymethyl)methane 
bp  -  base pair 
bt  -  bos taurus 
CARD  -  caspase recruitment domain 
cf  -  canis familaris 
CTD  -  C-terminal domain 
Cul4A  -  cullin RING ubiquitin ligase 4A 
DCAF  -  DDB1-Cul4-associated factors 
DDB1  -  DNA damage-binding protein 1 
DTT  -  dithiothreitol 
EMCV  -  encephalomyocarditis virus 
EMSA  -  electrophoretic mobility shift assays 
ER  -  endoplasmic reticulum 
FADD  -  Fas-associated protein with death domain 
gg  -  gallus gallus 
HEPES  -  4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid 
HIN  -  hemopoietic expression, interferon-inducibility, nuclear localization 
IFI16  -  interferon-inducible protein 16 
IκB  -  inhibitor of κB 
IKK  -  inhibitor of κB kinase 
IL  -  interleukin 
IPTG  -  isopropyl-β-D-thiogalactopyranoside 
IRF  -  interferon regulatory factors  
ISG  -  interferon stimulated genes 
LB  -  lysogeny broth 
LGP2  -  laboratory of genetics and physiology 2 
LPS  -  lipopolysaccharides 
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LRR  -  leucine rich repeats 
MAVS  -  Mitochondrial antiviral-signaling protein 
MDA5  -  melanoma differentiation associated protein 5 
mam  -  macaca mulatta 
mm  -  mus musculus 
MV  -  measles virus 
Mw  -  molecular weigth  
NF-κB  -  nuclear factor “kappa-light-chain-enhancer” of activated B-cells 
NLR  -  NOD-like receptors 
NLS  -  Nuclear localization signal 
NOD  -  nucleotide-binding and oligomerization domain 
NTD  -  N-terminal domain 
OAS  -  2’-5’ oligoadenylate synthase 
PAGE  -  polyacrylamide gel electrophoresis 
PAMP  -  pathogen-associated molecular patterns 
PCR  -  polymerase chain reaction 
PEG  -  polyethylene glycol 
PIV5  -  parainfluenza virus 5 
Pol III  -  RNA polymerase III 
poly(I:C)  -  polyinosinic:polycytidylic acid 
PPR  -  pattern recognition receptor 
PYD  -  pyrin domain 
PYHIN  -  pyrin and HIN domain 
RCL  -  reactive center loop 
RdRp  -  RNA-dependent RNA polymerase 
RIG-I  -  retinoic acid inducible gene I 
RING  -  really interesting new gene 
RIP  -  receptor-interacting serine/threonine-protein kinase 
Riplet  -  RING finger protein leading to RIG-I activation 
RLR  -  RIG-I like receptor 
ROS  -  reactive oxygen species 
SAD  -  single wavelength anomalous dispersion 
SAXS  -  Small-angle X-ray scattering 
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SF2  -  superfamily 2 
ss  -  sus scrofa 
STAT  -  signal transducers and activators of transcription 
STING  -  stimulator of interferon genes 
TBK1 - TANK-binding kinase 1 
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TIR  -  Toll/interleukin- 1 receptor 
TLC  -  thin layer chromatography 
TLR  -  Toll-like receptors 
TRADD  -  tumor necrosis factor receptor type-1 associated death domain 
TRAF  -  tumor necrosis factor receptor associated factors 
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VDC  -  V protein dependent degradation complexes 
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